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Panic disorder (PD) was officially introduced into the psychiatric nomenclature 
as a distinct illness in 1980 with the publication of the Diagnostic and Statistical 
Manual of Mental Disorders, third edition (APA, 1980). The central clinical 
features of PD are spontaneous panic attacks, involving numerous psycho-
logical and physical symptoms. PD is generally considered a chronic or inter-
mittent psychiatric condition which is often disabling (Keller et al., 1994, 
Batelaan et al., 2010). The illness leads to an increased use of health care 
services (Rief et al., 2005) as well as a significant loss in the quality of life and 
psychosocial functioning (Keller et al., 1994, Kessler et al., 2006; Roy-Burne et 
al., 2006, Mendlowicz et al., 2000). 
The expression of personality traits mainly related to anxiety and mood 
disorders is proposedly connected to serotonin mechanisms (Takano et al.2007). 
High levels of Neuroticism have been associated with increased serotonin 
binding within the thalamus (Takano et al.,2007) and 5HT1A receptor (Hirvonen 
et al., 2015) 
Personality traits can have some influence on the outcome of pharmaco-
therapy, which in turn can produce changes in personality. Studies have revealed 
contradictory results. Some initial reports on PD have indicated that a large 
improvement in panic symptoms after anxiolytic medication with alprazolam or 
diazepam is accompanied by significant changes in neuroticism-related perso-
nality traits (Reich et al., 1991, Noyes et al., 1986). On the contrary, studies by 
Carrera et al. (2006) postulated that none of the personality traits of panic 
disorder patients, assessed by the Neuroticism-Extraversion-Openness Five-
factor Personality Inventory (NEO-FFI) were related either to clinical severity 
or to a short-term response to SSRI treatment (Carrera et al., 2006). 
The relation between personality traits and the treatment outcomes of PD 
remains an important topic for physicians because, although progress has been 
made in the development of effective pharmacological and psychotherapeutic 
interventions, still not all patients respond to treatment (Katon et al., 2006). The 
high rate of treatment failure and relapses in treating PD patients possibly 
suggest personality diathesis (Powers and Westen, 2009). A more effective 
comprehension of the relationship between personality factors and PD can help 
to give a greater understanding of etiology, identify patients at risk of suffering 
Genetic, biological, environmental and psychosocial factors, including 
personality traits were found to play an important role in the development of the 
PD and influence treatment response (Andrisano et al., 2012, Carrera et al., 
2006). Furthermore, a study by Powers and Westen (2009) produced results that 
suggest the importance of personality in understanding the different phenotypes 
of panic patients (high functioning, emotionally dysregulated, inhibited/ avoidant, 
somatizing patients) and in making better predictions about responses to 
treatment (Powers, 2009). This point of interest was an important motivator for 
this dissertation. 
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from more resistant symptoms, and help to both plan treatment and prevent 
these conditions. 
The impact of personality traits on the risk of panic disorder and on its treat-
ment, as well as the stability of a personality disorder diagnosis, has continually 
been an object of discussion (Johnson et al., 2006; Mennin et al., 2000). 
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2. REVIEW OF THE LITERATURE 
2.1. Clinical characteristics and course of panic disorder 
Panic disorder (PD) is a serious anxiety disorder characterised by recurrent 
panic attacks and associated fearful anticipation of panic and its consequences, 
and frequently developing agoraphobia (DSM-IV, ICD-10). Panic attacks are 
defined as rapidly escalating occurrences of at least four out of 13 distressing 
symptoms including palpitations, sweating, trembling or shaking, shortness of 
breath or smothering, feeling of choking, chest pain or discomfort, nausea or 
abdominal distress, feeling dizzy, unsteady, lightheaded, or faint, derealisation, 
depersonalisation, fear of losing control or going crazy, fear of dying, 
paresthesias and chills or hot flushes. The identification of PD requires careful 
differential diagnosis from panic-like symptoms and autonomic arousal 
resulting from the direct physiological effects of substance use or a general 
medical condition and from symptoms of anxiety better explained by another 
mental health disorder. On the other hand, patients with PD have an increased 
risk of other psychiatric as well as medical morbidity. There is a high degree of 
PD comorbidity with other mental health disorders: 30–63% for major 
depression, 29.5–58.2% for agoraphobia, 20–75% for social phobia, 20% for 
generalised anxiety disorders, 14% for obsessive-compulsive disorder, 13% for 
bipolar disorder and 6% for post-traumatic stress disorder (Goisman et al., 
1994; Chen and Dilsaver, 1995; Pelissolo and Lepine 1998; Eaton et al., 1994; 
Wittchen et al., 1998; Weissman et al., 1997; Kessler et al., 1998; Kessler et al., 
2006; Lamers et al., 2011; Preti et al., 2018). Substance abuse is also a common 
comorbid disorder in up to 36% of cases according to Epidemiological 
Catchment Area data (Regier et al., 1998). In addition, PD often occurs together 
with cardiac, gastrointestinal, respiratory and neurological disorders (Zaubler 
and Katon, 1998). 
According to epidemiological surveys, sporadic panic attacks occur in the 
population at 7–15% the lifetime prevalence rate (Pelissolo and Lepine, 1998; 
Eaton et al., 1994), and are often associated with substantial morbidity even in 
the absence of a full clinical manifestation of PD (Klerman et al., 1991). The 
lifetime prevalence of PD rates are between 1.5% and 3.5%, while twelve-
month prevalence rates in females were found to be higher than in males (Eaton 
et al., 1994). In Estonia, the prevalence of panic symptoms among primary care 
patients is different among men and women, accordingly 5.5% for men and 8% 
for women (King et al., 2008) – a tendency that has been demonstrated in 
several studies. The age of onset of PD is usually in the mid-twenties, with 
hazard rates for females ranging from 25 to 34 years and for males between 30 
and 44 years (Wittchen and Essau, 1993). As with gender, data about PD is also 
different with age. Panic attacks were observed in 3% of youths aged from 9 to 
17 years (Goodwin and Gotlib 2004) and PD was diagnosed in 10–13% of 
clinically referred children and adolescents (Doerfler et al., 2007, Masi et 
12 
al.,2000). Lower rates of panic disorder are typically seen in persons aged 65 
and older (Robins, 1991, Kessler et al., 2006, Yates, 2009). 
PD has been recognised as a chronic condition with a fluctuating course 
(Liebowitz 1997; Pollack and Otto, 1997). Some studies have addressed longi-
tudinal aspects; for example, in a three-year follow-up only 10% of patients 
with PD were symptom-free (Noyes et al., 1990) and only 12% of PD patients 
were in full remission after five years (Faravelli et al., 1995). At follow-up, 
study revealed that 25–50% of PD patients relapse within 6 months after 
discontinuation of drug treatment (Pull and Damsa, 2008). There is evidence 
that the more important predicting factors of the course of panic disorder in the 
clinical population are not the severity and frequency of panic attacks, but rather 
long duration and agoraphobia at baseline (Katschnig and Amering, 1998). 
Predictors of remission were found to be female gender, the absence of ongoing 
difficulties, subthreshold panic and a low initial frequency of attacks (Katon, 
1987, Kessler 2006). 
PD can be a seriously disabling disorder that causes impairment in social, 
personal and occupational functioning and a significant loss of quality of life 
(Candilis et al., 1999). The rate of those PD patients who are dependent on 
welfare or disability benefits exceeds 25% in some studies (Katerndahl and 
Realini, 1997). Furthermore, medical utilisation rates among individuals with 
panic disorder appear disproportionately high (Barsky et al., 1999; Katerndahl 
and Realini, 1997, Zane et al., 2003). Panic disorder patients consulted their 
general practitioner significantly more often than the control group (Simpson et 
al. (1994). More frequent physician visits, emergency room visits and mental 
health visits were reported among patients with PD as compared to general 
medical outpatients (Barsky et al., 1999). Patients seek immediate medical care 
during initial panic attacks, commonly in the Emergency Department (ED), 
because these attacks are often interpreted as evidence of a catastrophic physical 
disorder, such as a myocardial infarction (Tueth, 1997; Dammen et al., 2001) or 
respiratory failure and uncomfortable feelings related to fear of death. This is 
the reason why patients who screen positive for panic disorder use emergency 
medical services and ED services more frequently (Zane et al., 2003) than the 
general population. Although only 60% of people with panic disorder seek care, 
32% of these patients present to EDs (Zun, 1997, Fleet et al., 1996). Approxi-
mately 35% of patients with PD visit their general family practitioner and 
continue to receive treatment with their primary physician, while only 26% of 
panic attack patients initially seek care in a mental health setting (Katerndahl 





2.2. Risk factors of panic disorder 
The pathogenesis of PD is complex and involves sociodemographic, psycho-
logical, biological and evolutionary factors. Marital status is a significant risk 
factor for PD: the highest lifetime prevalence rates are found in widowed, 
separated or divorced subjects (Wittchen and Essau 1993). In particular, about 
25% of subjects with PD had a previous divorce, compared to approximately 
10% of those with no active phase of disorder (Yates, 2009). There are no 
consistent findings concerning the educational level and the risk of developing 
PD, although Eaton et al. (1994) reported a tenfold higher risk for persons with 
less than 12 years of education. A high frequency of stressful life events also 
often precedes the onset of PD (Scocco et al., 2007). Several studies have 
suggested that life events such as early parental loss or childhood abuse may 
increase the risk of PD (Faravelli 1995; Tweed et al., 1989; Cougle et al., 2010, 
Goodwin et al., 2005b, Roy-Byrne et al., 1986; Assellmann et al., 2017). 
Furthermore, children with behavioural inhibitions may appear to have an 
increased risk for later development of PD (Reznick et al., 1992; Hirshfeld-
Becker et al., 2008). 
According to the cognitive theory of Clark (1986), individuals who expe-
rience recurrent panic attacks have a relatively enduring tendency to interpret 
certain bodily sensations in a catastrophic fashion. Barlow (1988) described 
panic as the basic emotion of fear, which is considered to be an acute reaction to 
perceived imminent danger when no danger is present. The false suffocation 
alarm theory by Klein (1993) suggested that PD patients have a low stimulation 
threshold of the asphisiostat, a physiological mechanism of protection from 
potentially lethal stimuli. One important vulnerability factor for anxiety dis-
orders, and in particular for PD, is anxiety sensitivity or fear of anxiety 
symptoms. Studies support the idea that anxiety sensitivity acts as cognitive 
predisposition for the development of PD (Schmidt et al., 1997). Gorman et al. 
(1989) were the first authors to propose a neuroanatomical model specific to 
PD. This aetiological model of PD suggested an abnormal sensitivity in the 
brain mechanism of a fear and alarm response involving a network of neuronal 
pathways and multiple neurotransmitter systems. According to this hypothesis, 
panic attacks originate from a dysfunction in the brain fear network that 
integrates various structures of the brainstem, hippocampus, amygdala, medial 
hypothalamus, thalamus and cortical regions. This model links acute panic 
attacks to the brain stem nuclei, anticipatory anxiety to limbic activation and 
kindling, and phobic avoidance to prefrontal cortical function, integrating 




2.3. Pharmacotherapy of panic disorder and  
treatment outcome 
Five classes of medication have been shown in randomised trials to be more 
effective than placebo in patients with panic disorder: selective serotonin-
reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors 
(SNRIs), high-potency benzodiazepines, tricyclic antidepressants and monoamine 
oxidase inhibitors (Mitte, 2005; Bradwejn, 2005; Otto et al., 2001; Gould et al., 
1995; Susman and Klee 2005; Goddard et al., 2001). A meta-analysis compared 
the efficacy of three pharmacologic classes of medications with placebo in 
patients with panic disorder as measured by levels of global anxiety (frequency 
of panic attacks, and agoraphobia) and depression: SSRIs (in 17 trials), tricyclic 
antidepressants (in 23 trials) and benzodiazepines (in 25 trials) (Mitte, 2005). 
The three classes of medication were equally effective in treating anxiety, but 
the effect of benzodiazepines in treating depression was marginally less than 
that of either tricyclic antidepressants or SSRIs (Mitte, 2005). Large studies 
have shown a clinically significant response (defined by a 50% decrease in the 
frequency of panic attacks or global anxiety) in 50 to 80% of patients treated 
with SSRIs, tricyclic antidepressants or benzodiazepines (Mitte, 2005). An earlier 
meta-analysis compared the effects of SSRIs or placebo in 12 randomised, 
controlled trials (Otto et al., 2001). SSRIs were significantly more effective than 
placebo in reducing global anxiety and the frequency of panic attacks; more 
than 50% of patients treated with SSRIs became panic-free in seven of nine 
studies reporting this outcome. In a large, placebo-controlled trial in patients 
with panic disorder, SNRI venlafaxine, at a dose of 75 to 225 mg per day, 
reduced the global severity of panic, anticipatory anxiety, and fear and 
avoidance of social activities on the basis of validated anxiety scales. However, 
the drug did not increase the likelihood of becoming free of panic (Bradwejn et 
al., 2005). Because of their safety profile, as compared with the safety profiles 
of tricyclic agents and monoamine oxidase inhibitors, SSRIs are recommended 
as the first drug option in the treatment of panic disorder (Otto et al., 2001, 
Working Group on Panic Disorder 1998). Because clinical experience suggests 
that many patients with panic disorder are hypervigilant regarding side effects, 
SSRIs should be started at low doses, with dose titration every five to seven 
days, as tolerated. Although the benzodiazepines continue to have an important 
role in the treatment of panic disorder, concern with respect to dependence, 
medication abuse, side effects, and the rapid re-emergence of symptoms after 
discontinuation have led to the recommendation that these agents should not be 
the first choice for treatment, but instead used “as needed” (Susman and Klee 
2005). 
The goal of treatment should be to eliminate panic attacks, if possible, because 
a partial response often results in continued avoidance of frightening situations 
and impairment in social functioning. Unfortunately, not all panic patients 
achieve remission, so under-treatment of PD remains a major problem (Lydiard, 
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2011). The literature review shows that 20–40% of PD patients treated phar-
macologically are unresponsive to therapies, similar to the 30–40% of patients 
treated with cognitive-behavioural therapy (van Apeldoorn et al., 2008). Even 
the integrated therapies are not able to substantially reduce the percentage of 
insufficient response in PD (van Apeldoorn et al., 2008). In short-term clinical 
trials, despite the different treatment options, 17–64% of participants with PD 
did not respond adequately to pharmacotherapy and continued to have PAs 
and/or exhibited negative behaviour related to PAs (Freire et al., 2016). 
Furthermore, follow-up studies demonstrate that 25–50% of patients relapse 
within 6 months after discontinuation of drug treatment, whereas 40–60% of PD 
patients show subclinical symptoms after 4–6 years of follow-up (Perna et al., 
2012; van Apeldoorn, 2008). At 12-year follow-up, patients with panic disorder 
without agoraphobia were most likely to show a recovery in all assessment 
points; however, rates of recurrence were similar for panic disorder both with 
and without agoraphobia (Bruce et al., 2005). Severe agoraphobic avoidance 
and the severity of depressive symptoms, particularly the recurrent form, are 
among the predictors of non-remission and poorer outcomes in PD patients 
(Bruce et al., 2005; Park et al., 2012; Batelaan et al., 2010, Slaap and den Boer, 
2001), along with co-morbidity with generalised anxiety disorder, or social 
phobia and severity of panic symptoms (Chavira et al., 2009), as well as the 
coexistence of PD and bipolar disorder (Lee, 2008). On the other hand, PD 
patients without agoraphobia had higher recovery rates, spent considerably less 
time in illness episodes and were less affected by comorbid conditions compared 
with patients with any of the other anxiety disorders (Bruce, 2005). 
 
 
2.4. Personality and panic disorder 
Personality is defined as the unique psychological qualities of an individual that 
influence a variety of characteristic behaviour patterns (both overt and covert) 
across different situations and over time (Gerrig and Zimbardo, 2002). Perso-
nality traits are defined as highly stable behaviour patterns (Kipper et al., 2009), 
traditionally conceptualised as having two components: temperament, which 
refers to biologically based, stable individual differences in emotion and its 
regulation, and character, which refers to individual differences due to sociali-
sation. However, as the distinctions between these constructs are questionable, 
the terms “personality” and “temperament” are now often used interchangeably 
(Caspi and Shiner 2006, Clark and Watson 1999). In recent years, some authors 
have questioned this stability, suggesting that personality characteristics can be 
influenced by acute psychiatric symptoms and by time frame (Seviewright et 
al., 2002, Cohrs et al., 2008). Personality characteristics have been described as 
dynamic constructs that develop over the lifespan and change in response to 
maturation and life circumstances (Fraley and Roberts 2005, Rothbart and Bates 
2006). A number of processes and factors contribute to stability and a change of 
personality. For example, genes are a considered as a main influence on 
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phenotypic stability of personality (Krueger and Johnson 2008, Kandler et al., 
2010). On the other hand, many of the mechanisms hypothesised to cause 
personality change (e.g., life events, the timing of various social roles, physical 
health and cultural values) can differ considerably across cultures (Chopik WJ, 
Kitayama S. 2018). A recent review showed that personality traits, especially 
Neuroticism and Extraversion, could change as a result of clinical interventions 
(Roberts et al., 2017). In contrast to personality traits, which are described in 
dimensional terms (i.e. less vs. more of a trait), specific personality disorders 
are instead categorical terms (i.e. presence vs. absence of “disorder”) (Brandes 
et al., 2006) and represent a severe disturbance in the characterological consti-
tution and behavioural tendencies of the individual, usually involving several 
areas of the personality, and nearly always associated with considerable personal 
and social disruption. Personality disorder tends to appear in late childhood or 
adolescence and continues to manifest into adulthood. 
The several models aim to explain the relationship between personality traits 
and major psychiatric disorders, such as depression and PD (Akiskal et al.1983, 
Klein et al., 2011, Clark et al., 1994, Freire et al., 2007, Krueger and Tackett, 
2003, Wachleski et al., 2008). In particular, the following models were pro-
posed by Klein et al. (2011): 
(a) The continuous/spectrum model, which considers that personality traits 
and major psychiatric disorders are epiphenomena of the same process, and the 
relationship between them is not hierarchical. This model proposes that 
associations between personality and psychopathology are found because these 
two constructs both occupy a single domain or spectrum, and psychopathology 
is simply a display of the extremes of normal personality function. Support for 
this model is provided by an issue of criterion ovrlap. For instance, two of the 
primary facet scales of neuroticism are “depression” and “anxiety”. Thus, the 
fact that diagnostic criteria for depression, anxiety and neuroticism assess the 
same content increases the correlations between these domains. 
(b) The precursor model, in which mental disorders and personality have 
similar etiology, personality predicts onset of disorder. 
(c) The common cause model proposes that Neuroticism and common 
mental disorders, such as depression and anxiety disorders, are related, though 
not directly, and they share etiology accounts, genetic and environmental 
determinants. 
(d) The “scar” hypothesis, in which the occurrence of mental disorders, such 
as PD and depression, could provoke permanent personality alterations, such as 
increased dependency or insecurity (Akiskal et al., 1983, Ormel et al., 2013). 
According to the scar model, episodes of a mental disorder ‘scar’ an individual’s 
personality, changing it in significant ways from premorbid functioning. An 
example of a scar effect would be a decrease in openness to experience fol-
lowing an episode of post-traumatic stress disorder. 
(e) The concomitant model proposes mental disorders shape personality and 
neuroticism, but the effect of psychopathology is temporary. After the episode 
has remitted, the effect disappeared. 
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(f) The pathoplasticity model views personality having a causal influence on 
depression after onset. 
(g) The predisposition or vulnerability model in which personality could 
facilitate the emergence of mental disorders and is, in fact, part of its etio-
pathogenesis. The vulnerability may be general, predisposing the person to a 
range of distress disorders, or be specific to a particular disorder (Blatt, 1974). 
High Neuroticism either causes the development of common mental disorders 
directly or enhances the impact of causal risk factors such as stressful life 
events. 
It is proposed that personality traits may play a crucial role in the onset and 
development of PD (Clark, Watson, and Mineka, 1994), whereby extremes of 
personality traits indicate greater dysfunction in patients with anxiety disorders 
(Brandes et al., 2006). An anxious temperament and anxiety-related personality 
traits may represent intermediate phenotypes that predispose to PD (Na et al., 
2011, de Ruiter, 1992). A strong relationship has been observed between high 
neuroticism and low positive emotions and PD (Bienvenu et al., 2001b; 
Bienvenu et al., 2004, Carrera et al., 2006, Zugliani et al., 2017). On the other 
hand, Introversion was found to be related to agoraphobia, but not to PD itself, 
while patients with agoraphobia tend to have higher Neuroticism, lower Extra-
version or both (Bienvenu et al., 2001a; Bienvenu et al., 2004, Bienvenu et al., 
2007). Other personality factors such as Openness, Agreeableness and Con-
scientiousness seem to be unrelated to PD (Bienvenu et al., 2001b, Enns and 
Cox, 1997, Carrera et al., 2006). The other reports indicate less Self-Directed-
ness and Cooperativeness (Izci et al., 2014) and more obvious Harm Avoidance 
and fatigability (Izci et al., 2014; Kennedy et al., 2001; Wiborg et al., 2005) in 
patients with PD compared to healthy controls. In addition, PD patients show 
characteristics that are related to a developmental deficit in the capacity to 
regulate negative affect (Diamond, 1987). In particular, they tended to be shy 
and inhibited in childhood, especially showing a clear difficulty in expressing 
aggressiveness (Almeida and Nardi, 2002). The personality traits in PD could 
be influenced by gender and psychiatric comorbidity. Thus, it was shown that 
females with PD had higher Extraversion scores and were more fearful of 
physical consequences of anxiety than males, while males scored higher on 
angry hostility and depression facets of Neuroticism (Foot et al., 2004). Further-
more, Neuroticism as well as Agreeableness and Extraversion, though not 
Conscientiousness or Openness, significantly differed in PD patients with one 
disorder from those with two or more disorders (Cuijpers et al., 2005). Several 
other studies also showed an accentuation of certain personality traits, including 
Harm Avoidance, Neuroticism and Extraversion, in PD patients with affective 
comorbidity as compared to those with PD only (Ampollini et al., 1997; 
Bienvenu et al., 2001a; Bienvenu et al., 2001b; Freire et al., 2007, Zugliani et 
al., 2017). Neuroticism and Extraversion have also shown a strong correlation 
with the accumulation and severity of depression and agoraphobia with PD 
(Zugliani et al., 2017). Taken together, studies indicate significant alterations in 
the personality profiles of patients with PD, which are more pronounced when 
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comorbid with affective disorders. In terms of coexisting personality disorders, 
the high rates of cluster B (antisocial, borderline, histrionic, and narcissistic) 
and cluster C (avoidant, dependent, and obsessive-compulsive) personality dis-
orders are reported in PD patients (Yates et el., 2009, Ozkan M, 2005; Skodol et 
al., 1995; Bienvenu et al., 2009; Bienveu, 2005, Grant, 2005). The stronger 
association was observed for borderline personality disorder (BPD, whereas 
80% of in-patients with BPD met the criteria of anxiety disorders, including 
48% having PD (Zanarini et al., 1998). Notably, that patients having PD with 
agoraphobia tend to have a higher prevalence of personality disorder diagnoses 
than those without agoraphobia (Reich, 1987; Iketani et al., 2002). 
 
 
2.5. Personality and treatment outcome in panic disorder 
Although personality traits and disorders are defined as highly stable behaviour 
patterns (Kipperet al., 2009), several authors have suggested that personality 
traits can be influenced by acute symptoms and by aging (Rocca et al., 2006, 
Corchs et al., 2008) or even change, in particular Neuroticism, under the effect 
of clinical intervention, pharmacotherapy or cognitive-behavioural therapy 
(Tang et al., 2009, Clark et al., 2003, Barlow et al., 2013).  
It should be noted that in contrast to depression the association between 
personality characteristics and treatment outcome in anxiety disorders, 
including PD, is less investigated and understood (Bienvenu and Brandes, 
2005). However, such a relationship seems to be bilateral where personality 
may modify response to treatment, but in turn the treatment can lead to certain 
changes in personality patterns. In particular, it has been shown that personality 
deviations may affect severity of the PD (Sokol et al., 1995, Ozkan et al., 2005), 
negatively influence treatment response (Slaap and den Boer 2001; Marchesi et 
al., 2006a) and contribute to a lesser decrease in specific panic and agoraphobic 
symptoms during a treatment course in comparison with PD without co-morbid 
personality disorders (Prasko et al., 2005). However, the evidence that perso-
nality disorders may worsen the prognosis of PD or lead to a longer treatment 
course (Prasko et al., 2005) is not supported by other observations (Hofmann et 
al., 1998). Controversial results have also been reported regarding the possible 
effect of personality traits on treatment outcome in PD. Therefore, Navarro et 
al. (2013) showed that borderline personality traits presenting in PD patients at 
the onset of the disease might worsen the response to pharmacological treat-
ment. In some other studies, only the borderline traits have negatively influen-
ced the remission of panic attacks following one-year treatment with SSRIs in 
PD patients, whereas the number of other personality traits did not affect the 
outcome of medication (Marchesi et al., 2006a; Hoffmann et al., 1998). In 
contrast, the borderline traits predicted a better treatment outcome at the six-
month follow-up observation, whereas obsessive-compulsive personality traits 
were negatively related to treatment outcome (Dreessen et al., 1994). As was 
suggested, the effect of personality on treatment outcome in PD may depend on 
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several factors, including methodological variations across studies, differences 
in duration of follow-up, applied medications and definition of PD remission 
(Marchesi et al., 2006a). Earlier, Dreessen et al. (1998) reviewed 15 studies in 
aiming to evaluate the influence of personality disorders on treatment outcome 
in anxiety disorders, including PD. They concluded that the short-term treat-
ment outcome (up to 3 months) of PD is not convincingly affected by the pre-
sence of categorical or dimensional personality disorder variables. Chavira et al. 
(2009) demonstrated that higher Neuroticism and higher anxiety sensitivity 
scores at baseline were associated with less probability of clinical improvement 
in 3 months in primary care patients with PD, which is in line with an earlier 
observation of Costa and McCrae (1985) from a 3-month follow-up study 
suggesting that lower Neuroticism scores at baseline predict better clinical 
improvement. Both prominent Neuroticism and higher harm avoidance seem to 
be the most important predictors of non-response to therapy with SSRIs, 
whereas higher Self-Directedness, Agreeableness and Cooperativeness predict a 
better response to drug treatment (Marchesi et al., 2006b). However, asso-
ciations between basic personality dimensions and PD treatment response are 
not univocal. None of the explored personality traits as assessed by the Neuro-
ticism-Extraversion-Openness Five-factor Personality Inventory was related 
either to clinical severity or to short-term response to SSRI treatment (Carrera et 
al., 2006), and no association between personality traits and PD symptom 
remission were found in other studies (Marchesi et al., 2006a). 
In terms of the treatment effect on personality patterns in PD, some first 
reports have indicated that a large improvement in panic symptoms after 
anxiolytic medication with alprazolam or diazepam is accompanied by 
significant changes in neuroticism-related personality traits (Reich et al., 1991; 
Noyes et al., 1986). A positive influence on personality disorder characteristics 
in PD was also observed during both individual CBT and imipramine treatment; 
however, the efficacy was predicted by temperament (Hofmann et al., 1998). A 
more recent relatively small prospective study found that improvement in the 
symptoms of PD after 1year treatment with SSRIs was associated with the 
normalisation of paranoid traits and persistence of avoidant and dependent 
characteristics, suggesting that some personality traits in PD show, at least in 
part, a state phenomenon (Marchesi et al., 2005). In the later study by Marchesi 
et al. (2008,) higher levels of harm avoidance were found after 1 year of 
pharmacological therapy in patients with PD in remission compared to healthy 
controls. A recent study that used the SSP scale to evaluate the effect of 12-
weeks of internet-based cognitive behaviour therapy on severe health anxiety 
has shown a significant reduction on neuroticism related scales, whereas traits 
relating to extraversion and aggression remained largely unchanged (Hedman et 
al., 2014). On the contrary, a significant decrease was observed in all anxiety-
related scores as well as in the aggression and hostility-related scores on the 
Karolinska Scales of Personality (KSP) in PD patients after 6 months of treat-
ment with SSRI citalopram (Neuger et al., 2002). Additionally, a significant 
decrease in the score on 8 of the 10 Minnesota Multiphasic Personality Inven-
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tory scales was observed in PD patients following pharmacological treatment. 
However, the anxious and neurotic personality characteristics were still more 
pronounced in asymptomatic patients as compared to healthy controls (Kipper 
et al., 2009). Notably, although Brandes et al. (2006) revealed that remission 
from PD is generally associated with partial “normalization” of personality 
traits, some others assumed that personality traits remain stable over the course 
of PD (Morey et al., 2010, Santor et al., 1997). 
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3. RATIONALE FOR THE STUDIES 
The relationship between personality and PD is still poorly understood and has 
become a topic of scientific debate and scrutiny. Considering that most of the 
studies cited above included relatively small samples and provided only 
preliminary or controversial evidences, further extensive investigations are 
warranted to evaluate the involvement of personality disposition in the course 
and treatment of PD. Furthermore, there is a vast number of studies that have 
sought to identify predictors of treatment response in anxiety disorders, 
including PD. Although, these studies have not as yet yielded findings that were 
robust enough to be clinically relevant, there is a strong belief that predictors of 
treatment response would contribute to the personalised medicine approach and, 
particularly, guide decision making in selection of the most suitable medication 
for individual patients. Moreover, similarly to other putative predictors, 
including demographic and clinical characteristics, personality traits are easy to 
evaluate and not as costly as genetic or neuroimaging biomarkers, which 
significantly facilitate the implementation of personality assessment in routine 
practice. In particular, a better understanding of the relationship between 
personality traits, a course of PD and its treatment outcome may significantly 
improve the prediction and management of this prevalent and highly disabling 
anxiety disorder. Furthermore, personality traits seem to play a crucial role in 
the pathogenesis and prognosis of all mental health disorders. Therefore, the 
further exploration of personality traits in patients with mental disorders, 
including PD, would have an important impact on fundamental knowledge 
about the development and course of these diseases. In particular, to achieve the 
goals of the current work, we chose the Swedish universities Scales of Perso-
nality (SSP) to measure the personality traits in PD patients. The SSP is a self-
rated questionnaire based on the Karolinska Scales of Personality (KSP), an 
instrument designed to measure stable personality traits related to psycho-
pathology (Schalling 1978; Gustavsson et al., 2000). The KSP scales tap perso-
nality traits that have biological correlates and could contribute to the develop-
ment of mental disorders (Schalling et al., 1987; Klinteberg et al., 1987). 
Although the KSP does not aim to cover all aspects of personality, it charac-
terises four fairly general temperament dimensions: anxiety, extraversion, 
socialisation and aggression (Schalling et al., 1987). During development of the 
SSP, some aggression and neuroticism-related scales of the KSP were dropped 
due to unsatisfactory psychometric properties. The final version of the SSP 
comprised 13 scales that demonstrated good psychometric properties in the 
Swedish normative sample (Gustavsson et al., 2000). Four scales of the SSP 
assess various aspects of vulnerability to anxiety. Another five scales reflect 
aggression and related traits. The remaining scales characterise sensation 
seeking, impulse control, relation to the social environment and conformity. 
Factor analysis suggests that the SSP scales measure three broader constructs: 
neuroticism, extraversion and aggressiveness (Gustavsson et al., 2000). The 
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SSP has shown to be useful as a personality measure in psychobiological research 
(Damberg et al., 2003, Jönsson et al., 2003). A widely accepted approach in the 
field of personality structure research is the five-factor model (Costa and 
McCrae1992b), which proposes that most individual differences in personality 
can be understood in terms of five basic dimensions. Relating the personality 
traits measured by the SSP with the five-factor model could give a better 
understanding of the position of these traits in the basic structure of personality. 
One of the standard instruments designed to measure these five factors and their 
facets is the Revised NEO Personality Inventory (NEO-PI-R). The NEO-PI-R 
has demonstrated a similar structure in various cultures (McCrae and Costa 
1997). The SSP intends to measure temperament-like features, meaning that it 
also should be applicable in different social and cultural contexts. At the same 
time, the reliability and factor structure of the SSP in samples with different 
language and cultural backgrounds have not yet been studied. Thus, we aimed 
to test the reliability and validity of the Estonian version of the SSP. This also 
allows us to investigate the universality of the personality factors assessed by 
the SSP in a different social and cultural background. We also intend to charac-
terise the position of SSP-measured traits within the basic personality dimen-
sions of the five-factor model. Taken together, we found the SSP to be a 
promising instrument for its clinical exploitation in the evaluation of personality 
traits among patients with PD. 
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4. AIMS OF THE STUDIES 
The general objective of the present work was to characterise the personality 
traits of patients with PD and to explore the relationship between personality 
disposition and treatment outcome in those patients by using validated SSP 
assessment. The specific aims were, as follows: 
1. To test the reliability and validity of the Estonian version of the SSP (I) 
2. To characterise the position of SSP-measured traits within the basic 
personality dimensions of the five-factor model (I)   
3. To identify the differences in personality traits evaluated by SSP between 
patients with PD and healthy subjects (II) 
4. To examine differences in personality dimensions between PD patients with 
and without affective comorbidity, and explore the relationship between SSP 
personality domains and various demographic and clinical variables of PD 
(II) 
5. To examine the effect of escitalopram treatment on personality traits in PD 
patients (III) 
6. To identify whether the treatment outcome of PD could be predicted by any 
personality trait as measured by using SSP (III) 
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5. MATERIALS AND METHODS 
5.1. Subjects 
A total of 529 subjects participated in the study I, among them 174 (32.9%) 
men and 355 (67.1%) women. The average age was 35.7 years (standard 
deviation, s=14.0 years, range 18–74). The study group was formed of two 
samples. Sample 1 consisted of 331 healthy volunteers (106 men, 225 women, 
average age 39.1, s=13.5) who participated in different research projects 
conducted at the Department of Psychiatry of the University of Tartu. The 
absence of psychiatric disorders in this sample was confirmed by the Mini Inter-
national Neuropsychiatric Interview (M.I.N.I. 5.0.0; Sheehan et al., 1998). 
Sample 2 was a convenience sample comprising 198 subjects with various 
educational and social backgrounds (68 men, 130 women, average age 30.1 
years, s=12.9). The sample consisted of university students, their acquaintances, 
relatives and workmates. 
The study II sample consisted of 193 patients (45 men, 148 women, average 
age 36.9, s=12.3) with PD recruited at the Psychiatry Clinic of the Tartu 
University Hospital and 314 healthy subjects (94 men, 220 women, average age 
38.9, s=13.8) recruited by newspaper advertisement in Tartu, Estonia. Diagnosis 
of PD according to DSM-IV criteria was verified using the Mini International 
Neuropsychiatric Interview (M.I.N.I. 5.0.0; Sheehan et al., 1998) and sub-
stantiated by psychiatric history and medical records. At the time of assessment, 
126 of patients (65.3%) had current symptoms of PD and 67 were in remission. 
PD patients with current or past comorbidity with mood disorders or with other 
anxiety disorders were included in the study, but no other psychiatric comorbidity 
was allowed. Personality disorder was not assessed, it may be considered as 
limitation of the study. According to the clinical assessments 71 (36.8%) patients 
were defined as “PD only” group, who never met criteria for any other 
psychiatric diagnosis, with the exception of agoraphobia. The remaining 122 
patients (63.2%) with comorbid mood or anxiety disorders were defined as “PD 
comorbid” group. Major depressive disorder was the most frequent comorbid or 
lifetime co-existing condition, which was diagnosed in 93 patients (with its 
current presence in 60 patients); whereas the criteria for bipolar disorder were 
met in 29 patients (with its current presence in 7). Other anxiety disorders, 
including social phobia and obsessive-compulsive disorder, were detected in 46 
patients. Concurrent agoraphobia was present in 115 (59.6%) of the patients, 
among them 46 were from “PD only” and 69 from “PD comorbid” group. The 
earlier onset of PD with first panic attacks before age of 30 years was observed 
in 106 patients, whereas in 87 patients PD has developed in later lifetime 
period. The healthy subjects were interviewed using the M.I.N.I. and questioned 
about their family psychiatric history. Only those without personal or family 
(defined as first-degree relatives) history of psychiatric disorders were included 
in this study. The majority of the subjects were of Estonian ethnicity with a 
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similar between-group distribution (99% among patients and 95% among 
controls). 
The study III sample consisted of 110 adult patients with PD. Participants 
were recruited at the Psychiatry Clinic Outpatient Department or through 
referral from the Emergency Department of the North Estonia Regional 
Hospital. Three patients were excluded (two by patient request, one lost to 
follow-up); therefore, 107 PD patients (mean age = 34, s = 11.7 years; 71 
females) were included in the final sample of the study. The diagnosis of PD 
according to the DSM-IV criteria was verified using the Mini International 
Neuropsychiatric Interview and substantiated by psychiatric history and medical 
records. PD patients with current or past co-morbidity with mood disorders or 
with other anxiety disorders were allowed to take part in the study. However, 
other problems, such as schizophrenia or another psychotic disorder, severe 
suicide risk, substance abuse or dependence, organic mental disorder, severe 
personality disorder, serious unstable medical condition (i.e. endocrinological, 
liver, respiratory, cardiovascular diseases), were excluded. The majority of the 
subjects were of Estonian ethnicity (84.1%). All patients were unmedicated and 
did not receive any formal psychological help for at least 3 months before this 
trial and during the investigation. 
 
 
5.2. Ethical considerations 
The Human Studies Ethics Committee of the University of Tartu approved the 




5.3.1. The Mini International Neuropsychiatric Interview (M.I.N.I.5.0.0.) 
Diagnosis of PD and psychiatric co-morbidity according to DSM-IV criteria was 
verified using the Mini International Neuropsychiatric Interview (M.I.N.I.5.0.0.; 
Sheehan et al., 1998) and substained by psychiatric history and medical records 
(II, III). The Mini International Neuropsychiatric Interview (M.I.N.I.) is a 
structured diagnostic interview, developed for DSM-IV and ICD-10 psychiatric 
disorders. In 1999 M.I.N.I. 5.0.0. was adapted to Estonian at the Department of 
Psychiatry of Tartu, University of Tartu (Shlik et al.,1999). The absence of 
psychiatric disorders in sample of healthy subjects in control group (I, II) was 
confirmed by the M.I.N.I.5.0.0.; also subjects were questioned about their 





5.3.2. Swedish universities Scales of Personality (SSP) 
The Swedish universities Scales of Personality (SSP) is a self-rated question-
naire based on the Karolinska Scales of Personality (KSP) designed to measure 
stable personality traits related to psychopathology (Gustavsson et al., 2000). 
The SSP comprises of 91 items grouped into 13 scales: Somatic Trait Anxiety 
(STA), Psychic Trait Anxiety (PsTA), Stress Susceptibility (SS), Lack of 
Assertiveness (LA), Impulsiveness (I), Adventure Seeking (AS), Detachment 
(D), Social Desirability (SD), Embitterment (Em), Trait Irritability (TI), 
Mistrust (M), Verbal Trait Agression (VTA), and Physical Trait Aggression 
(PHTA). Each scale is formed by 7 items rated on a scale of 1 = does not apply 
at all, to 4 = applies completely. 
The factor analysis of the original SSP yielded three factors: neuroticism, 
aggressiveness and extraversion (Gustavsson et al., 2000). 
The raw scores were converted into T-scores using the raw score means and 
standard deviations of men and women from Estonian normative sample in 
study I. Only T-scores were used in the analysis in studies II and III. 
All participants self-evaluated their personality traits using the Estonian 
version of SSP (I, II, III) (Aluoja et al., 2009). 
(I) The SSP was completed by all participants of the study (both samples). 
(II) At the time of assessment all the patients (with current symptoms of PD 
and in remission) and all the control subjects completed the Estonian 
version of SSP to evaluate their personality traits. 
(III) The Estonian version of SSP was completed by study group twice, at the 




5.3.3. The revised NEO Personality Inventory (NEO-PI-R). 
The NEO-PI-R is a 240-item self-report questionnaire that measures personality 
structure according to the five-factor model (Costa&McRae, 1992b). Similarly 
to the original, the Estonian version of the NEO-PI-R (Kallasmaa et al., 2000) 
provides scores on the five personality dimensions: Neuroticism (N), Extra-
version (E), Openness (O), Agreeableness (A), and Conscientiousness (C). Each 
personality domain is composed of six facet scales. Responses are made on a 
five-point Likert-type scale (from strongly agree to strongly disagree). One of 
the standard instruments designed to measure these five factors and their facets 
is the Revised NEO Personality Inventory (NEO-PI-R) (Costa et al., 1992). 
NEO-PI-R has demonstrated similar structure in various cultures (McCrae& 
Costa 1997). In study I 197 subjects from the Sample 2 completed Estonian 
version of the NEO-PI-R. 
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5.3.4. Panic Disorder Severity Scale (PDSS) 
The PDSS (Shear et al., 1997) is used for assessment of clinical severity and 
treatment response of PD. The PDSS is seven-item measure, score range 0–28, 
comprised of five items assessing core DSM-IV symptoms of PD, with or wit-
hout agoraphobia, and two items rating work and social impairment (Shear et 
al., 1997). The scale has been considered sensitive to change with medication 
treatment (Pollack et al., 1998). The scale has been translated into several 
languages and findings strongly support the reliability and validity of the PDSS 
in different cultural background (Shear et al., 2001, Lee et al., 2009, Barlow et 
al., 2000). For screening of patients a cut-off score 8 was recommended, which 
identifies patients with current PD with a sensitivity of 83.3% and a specificity 
of 64% (Shear et al., 2001). The PDSS score 7 or less has been used in several 
studies for defining of remission (Furukawa et al., 2009, Shear et al., 2001, Park 
et al., 2012, Seki et al., 2016) and is considered the point of remission in this 
study. All patients in the study III were assessed using the PDSS beginning 
from the baseline up to the endpoint of the study in every two weeks. 
 
 
5.3.5. The Clinical Global Impression scale (CGI) 
The Clinical Global Impression scale (Guy, 1976) is a 3-item observer-rated scale 
commonly used to measure symptom severity, global improvement, and thera-
peutic response. Each component of the CGI is rated separately. The Clinical 
Global Impression – Severity scale (CGI-S) is a 7-point scale to rate the severity 
of patient illness at the time of assessment, relative to the clinician’s past 
experience with patients who have the same diagnosis. Considering total clinical 
experience, a patient is assessed on severity of mental illness at the time of 
rating 1, normal, not at all ill up to 7, extremely ill. 
The Clinical Global Impression – Improvement scale (CGI-I) is a 7 point 
scale for assessment how much the patient’s illness has improved or worsened 
relative to a baseline state at the beginning of the intervention and rated as: 1, 
very much improved; 2, much improved; 3, minimally improved; 4, no change; 
5, minimally worse; 6, much worse; or 7, very much worse. 
The Clinical Global Impression – Efficacy Index is a 4 point × 4 point rating 
scale that assesses the therapeutic effect of the treatment as 1, unchanged to 
worse; 2, minimal; 3, moderate; 4, marked by side effects rated as none, do not 
significantly interfere with patient’s functioning, significantly interferes with 
patient’s functioning and outweighs therapeutic effect. With this scale 
therapeutic efficacy and treatment-related adverse events should be taken into 
account. Clinical severity and treatment response in the study III were assessed 
using the CGI, every two weeks during the study. 
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5.3.6. Hamilton Anxiety Scale (HAM-A) 
Hamilton Anxiety Scale (HAM-A) (Hamilton, 1959) was developed to measure 
the severity of anxiety symptoms and is widely used in clinical and research 
settings. The HAM-A is an interview-based scale, consists of 14 items, each 
defined by a series of symptoms, and measures psychic anxiety (mental agitation 
and psychological distress) and somatic anxiety (physical complaints related to 
anxiety). Each item is simply given a 5-point score – 0 (not present) to 4 
(severe). HAM-A was used as a secondary scale in the study III for clinical 
assessments, every two weeks during the study. 
 
 
5.3.7. Toronto Side-effect Scale (TSES) 
Toronto Side-effect Scale (TSET) is a 32-item instrument used to evaluate 
possible adverse events, incidence, frequency, and severity of central nervous 
system, gastrointestinal, and sexual side effects (Vanderkooy et al., 2002). 
TSES was used as a secondary scale for clinical assessments in the study III, 
every two weeks during the study. 
 
 
5.3.8. The Emotional State Questionnaire (EST-Q) 
The Emotional State Questionnaire (EST-Q) (Aluoja et al., 1999) is a self-rated 
questionnaire, constructed on the basis of the relevant diagnostic criteria in the 
DSM-IV (APA, 1994) and the 10th revision of the International Classification 
of Diseases and Related Health Problems (ICD-10, World Health Organization 
1993). The EST-Q contains 28 questions in five subscales; items are rated on a 
5-point frequency scale ranging from 0 (never) to 4 (continuously). 
 
 
5.3.9. Sociodemographic measures 
Data on sex, gender, age, years of education, employment, smoking habit, alcohol 
drinking frequency, presence of somatic co-morbidities and marital status were 





The patients in the study III were treated with 10–20 mg/day of escitalopram for 
12 weeks using an open-label placebo non-controlled study design. No other 
medications were permitted during the treatment period, except for hormonal 
contraceptives. Additionally, zolpidem or zopiclon for insomnia and alprazolam 
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for acute anxiety or panic symptoms were also allowed during the first 6 weeks. 
All patients started the treatment with a dose of 10 mg/day of escitalopram for 
the first 4 weeks. The patients who showed at least a 50% decline in the PDSS 
total score at week 4 continued taking 10 mg of escitalopram until the end of the 
study. The dose of escitalopram was increased and maintained at 20 mg in 
patients who demonstrated less than a 50% decrease in PDSS total score at 
week 4. At the end of week 12, remission was defined as a patient who meets 
all three criteria – the score on the CGI improvement scale 2 or less, the PDSS 
score 7 or less – the cut-off point, used in several studies for defining of remis-
sion, and no panic attacks for at least the last 2 weeks. Patients who did not 
meet these criteria were defined as non-remitters. The severity of the panic 
symptoms and treatment response were rated by a psychiatrist (UV), who was 
blind to the personality trait measures. During each visit, the patients were also 
asked to report on their regularity of taking the medication. Adherence to 
medication was good – by patients self-report none of the patients had more 
than 3 days drug holiday. 
 
 
5.5. Statistical analysis 
The data were analyzed using the software package STATISTICA 8 (StatSoft 
Inc., Tulsa, OK, USA) and statistical software R 3.1.1. (R Core Team, 2014). In 
the study I the internal consistency of the SSP scales was assessed by 
calculating Cronbach's α coefficients. To evaluate the factorial validity of the 
SSP a principal component analysis with a varimax rotation was conducted on 
the scales. The factors were extracted on the basis of an eigenvalue greater than 
one. In subsample 2 the external validity of the SSP was evaluated by calcu-
lating Pearson product moment correlations between the SSP scales and the 
NEO-PI-R scales. Correlations between the SSP and NEO-PI-R scale facets 
were reported only if they provided additional information for understanding of 
the SSP scales. Student's t-test was used to evaluate sex differences. In the study 
II the non-parametric tests, including Chi-squared, Fisher’s exact test and 
Mann-Whitney U-test, were used as appropriate. Correlations were estimated 
with Pearson product-moment correlation analysis. Multiple logistic regressions 
were used to analyze the relative influence of personality variables. Only 
variables which showed a significant relationship with PD in univariate analyses 
were entered into multivariate models. Three broader factors, neuroticism, extra-
version and aggressiveness, were included in our analysis. The comparisons of 
SSP subscales and factors were performed for all patients and separately for 
subgroups of those with and without comorbidity. The comparisons of SSP 
traits and factors were also done in patient subgroups divided according to pre-
defined clinical phenotypes (current PD versus remission status, presence or 
absence of agoraphobia, early or late onset of PD, presence or absence of family 
psychiatric history). The results of between-group comparisons of SSP scores 
were considered nominally significant at p<0.05 level with a conservative 
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estimation of significance after Bonferroni correction for multiple comparisons 
on 13 SSP traits at p<0.00384 level. In the study III baseline and final SSP sub-
scales were described by mean, minimum and maximum, Wilcoxon signed rank 
test was used to test the significance of the change between the end and baseline 
scores of the study. The association between the baseline scores of SSP sub-
scales and the changes of PDSS, CGI-S, HAM-A and EST-Q depression was 
evaluated using partial correlation coefficients with 95% confidence intervals 
(CI). Similarly, the association between changes in the scores of SSP sub-scales 
and changes of PDSS, CGI-S, HAM-A and EST-Q depression was evaluated 
using partial correlation coefficients with 95% CI. The association between the 
baseline scores of SSP sub-scales and the probability of good treatment 
response (final PDSS≤7) was analysed by binary logistic regression resulting in 
odds ratios (OR) with 95% CI. All of the analyses of associations were adjusted 
for sex, age, years of education, level of drinking frequency, presence of somatic 
co-morbidities and for the presence of mild depression and/or agoraphobia. The 
resulting p-values were considered nominally significant at p<0.05 level; the 
Holm-Bonferroni correction for multiple comparisons was used. Regression 
assumptions were checked by graphical methods, where applicable. 
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6. RESULTS AND DISCUSSION 
6.1. Study I: Factor structure of the Swedish  
universities Scales of Personality and position  
within the five-factor model in an Estonian sample 
6.1.1. The gender differences for the SSP 
Mean values of the SSP for the whole study sample and separately for males 
and females are presented in Table 1. Females scored significantly higher on 
Psychic Anxiety, Stress Susceptibility, Lack of Assertiveness, and Social 
Desirability. Men scored higher on Verbal and Physical Aggression, Mistrust, 
and Adventure Seeking. The highest gender differences emerged for Aggression 
and Anxiety scales. Internal consistency coefficients for the SSP scales ranged 
from 0.58 (Detachment) to 0.85 (Trait Irritability). 
 
Table 1. Means, standard deviations, Cronbach alphas, and gender differences for the 
SSP scales 
SSP scales Total   Men  Women t 
 Mean s (α) Mean s Mean s  
Somatic Trait Anxiety 1.84 0.54 0.75 1.82 0.52 1.84 0.55 0.39 
Psychic Trait Anxiety 2.17 0.59 0.82 2.03 0.56 2.24 0.60 4.00‡ 
Stress Susceptibility 2.17 0.50 0.73 2.11 0.50 2.20 0.49 1.97* 
Lack of Assertiveness 2.35 0.48 0.64 2.28 0.48 2.39 0.48 2.64† 
Impulsiveness 2.42 0.45 0.62 2.42 0.43 2.42 0.46 0.17 
Adventure Seeking 2.63 0.56 0.80 2.71 0.55 2.59 0.56 –2.21* 
Detachment 2.23 0.44 0.58 2.27 0.44 2.21 0.44 –1.62 
Social Desirability 3.05 0.41 0.66 2.95 0.39 3.09 0.41 3.81‡ 
Embitterment 1.99 0.49 0.73 2.00 0.51 1.99 0.48 –0.30 
Trait Irritability 2.30 0.61 0.85 2.33 0.58 2.28 0.63 –0.99 
Mistrust 2.11 0.50 0.76 2.21 0.49 2.06 0.49 –3.34† 
Verbal Trait Aggression 2.32 0.59 0.78 2.51 0.57 2.23 0.57 –5.45‡ 
Physical Trait 
Aggression 
2.10 0.62 0.84 2.44 0.60 1.93 0.57 –9.54‡ 





6.1.2. The principal component analysis of the SSP scales 
Present study yielded three factors in analysis of the SSP scales, with an 
eigenvalue greater than unity, accounting for 62.9% of the total variance 
(Table 2). The first factor grouped scales that characterise neuroticism, 
accounting for 27.8% of the variance. Both forms of Trait Anxiety (somatic and 
psychic), Stress Susceptibility, Lack of Assertiveness, and Embitterment had 
highest loadings on this factor. The second factor accounted for 20.2% of the 
variance and included Verbal and Physical Trait Aggression, Trait Irritability, 
Detachment, and low Social Desirability, thus indicating aggression and 
nonconformity. Although Detachment and Trait Irritability had highest loadings 
on the second factor, they also loaded somewhat on the third and the first 
factors. The third factor comprised Impulsiveness and Adventure Seeking, 
accounting for 14.8% of the variance. Mistrust loaded nearly equally on two 
factors, relating to neuroticism and aggression. 
 
Table 2. Results of the principal component analysis with a varimax rotation of the SSP 
scales 
Scales Factor 1* Factor 2* Factor 3* 
Somatic Trait Anxiety 0.68 0.26 0.29 
Psychic Trait Anxiety 0.89 0.08 0.01 
Stress Susceptibility 0.76 0.25 –0.03 
Lack of Assertiveness 0.80 –0.14 –0.09 
Impulsiveness 0.20 0.22 0.75 
Adventure Seeking –0.03 0.07 0.79 
Detachment 0.38 0.50 –0.40 
Social Desirability –0.14 –0.70 0.04 
Embitterment 0.65 0.31 0.20 
Trait Irritability 0.49 0.58 0.36 
Mistrust 0.51 0.50 0.01 
Verbal Trait Aggression 0.05 0.72 0.47 
Physical Trait Aggression 0.03 0.70 0.29 
* Items defining the factors are boldfaced 
 
 
6.1.3. The correlations between the SSP and NEO-PI-R scales 
The correlations between the SSP scales and the five dimensions of personality 
assessed by the Estonian NEO-PI-R are shown in Table 3. Due to the large 
number of correlations performed, Bonferroni adjusted alpha of p<0.001 was 
applied to correlation coefficients. NEO-PI-R domain Neuroticism correlated 
mainly with SSP neuroticism factor scales. The strongest relationships were 
found with Psychic Trait Anxiety and Stress Susceptibility. Extraversion related 
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positively to Adventure Seeking and Impulsiveness, and negatively to 
Detachment, Psychic Anxiety, Lack of Assertiveness, Stress Susceptibility, and 
Mistrust. Agreeableness correlated positively with SSP Social Desirability and 
negatively to Aggression-Irritability scales, Mistrust, and Embitterment. NEO-
PI-R dimensions Openness and Conscientiousness had somewhat weaker corre-
lations with the SSP. Conscientiousness related highest to Social Desirability, 
and Openness to Adventure Seeking. Two SSP scales, Impulsiveness and 
Physical Trait Aggression had only one moderate correlation with NEO-PI-R 
domains. To get a better understanding of the relationships of SSP scales with 
five factors we also looked at the correlations with NEO-PI-R facet scales. SSP 
Impulsiveness correlated positively with Neuroticism facets Impulsiveness 
(r=0.44) and Hostility (r=0.32), Extraversion facets Assertiveness (r=0.29), 
Activity (r=0.24), Excitement-Seeking (r=0.31), and Positive Emotions 
(r=0.29), and negatively with Agreeableness facets Compliance (r=0.32) and 
Modesty (r=–0.31). The highest negative correlation emerged between Impul-
siveness and Deliberation (r=–0.54), which is a facet of Conscientiousness. SSP 
Physical Trait Aggression correlated positively with Neuroticism facet Hostility 
(r=0.34), and negatively with Agreeableness facets Trust (r=–0.25), Straight-
forwardness (r=–0.34), and Compliance (r=–0.54). 
 
Table 3. Correlations between the SSP and the NEO-PI-R scales in sample 2 (n=197) 
 N E O A C 
Somatic Trait Anxiety 0.61* –0.20 –0.12 –0.24 –0.23 
Psychic Trait Anxiety 0.76* –0.48* –0.25* –0.04 –0.23 
Stress Susceptibility 0.67* –0.44* –0.19 –0.10 –0.38* 
Lack of Assertiveness 0.44* –0.45* –0.27* 0.19 –0.17 
Impulsiveness 0.13 0.35* 0.10 –0.19 –0.19 
Adventure Seeking –0.03 0.53* 0.32* –0.16 –0.02 
Detachment 0.30* –0.67* –0.35* –0.20 –0.13 
Social Desirability –0.35* 0.21 0.02 0.52* 0.46* 
Embitterment 0.65* –0.22 –0.23 –0.32* –0.35* 
Trait Irritability 0.55* –0.12 –0.08 –0.50* –0.28* 
Mistrust 0.48* –0.36* –0.26* –0.43* –0.18 
Verbal Trait Aggression 0.27* 0.10 0.15 –0.60* –0.27* 





The aim of this study was to test the reliability and validity of the Estonian 
version of the SSP in order to use the scales in further studies of the role of 
personality factors in mental disorders. Thus, we evaluated the Estonian SSP in 
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reference to the Swedish original data, and we characterised the position of the 
SSP-measured traits within the basic personality dimensions of the five-factor 
model. The internal consistency of the Estonian SSP scales was in an acceptable 
range and resembled the Swedish normative data (Gustavsson et al., 2000). The 
range of the Cronbach α coefficients was between 0.59 and 0.84 in the Swedish 
study, while they ranged from 0.58 to 0.85 in the Estonian sample. The internal 
consistency of the anxiety and aggression scales was good and comparable with 
the original sample. Only two scales, Detachment and Impulsivity, had some-
what low internal consistency. General trends in sex differences were similar in 
the Estonian and Swedish samples: women scored higher on neuroticism-related 
scales and men on aggression scales. The one exception was not finding gender 
differences in the Detachment scale, while in Swedish KSP and SSP studies 
men have consistently scored higher on detachment than women (Gustavsson et 
al., 2000; Gustavsson 1997). 
The Estonian data revealed a similar three-factor structure of the SSP that 
was found in the Swedish sample. The Neuroticism factor was identical in the 
two studies. This finding is important, as clinical researches have identified 
neuroticism as one of the key contributors to psychopathology (Lahey, 2009). 
Although the SSP was constructed more for the assessment of psychopathology 
and the NEO-PI-R for normative personality, both contain Neuroticism factors 
that are strongly correlated. This also confirms the universality of the general 
Trait of Neuroticism. 
We found analogous factors to Aggression and Extraversion of the Swedish 
sample (Gustavsson et al., 2000), except for Detachment scale, which according 
to the Swedish data loaded negatively into the extraversion factor but in our 
study was closer to aggression. An ambiguous nature of Detachment scale has 
been earlier observed in factor-analytical studies of the KSP. Some studies 
indicated that Detachment was a sign of low sociability and thus related to 
Extraversion (Schalling et al., 1987, Zuckerman et al., 1991), whereas other 
studies showed its relatedness to Irritability, low Social Desirability and Suspicion 
(Gustavsson et al., 1997; Ortet et al., 2002). These results probably reflect the 
complex nature of the construct of Detachment, which is a tendency to avoid 
close contacts but is also related to the perception of others as being hurtful or 
untrustworthy (Bornstein et al., 2003). The latter aspect is related to an 
affective-cognitive side of aggression (irritability and hostility), but not neces-
sarily to its behavioural component represented by Verbal and Physical Aggres-
sion scales of the SSP. It is of interest that Detachment and Irritability may even 
have some common biological correlates (Stalenheim, 2004). 
The Neuroticism factor of the SSP is represented in major models of 
personality (Costa and McCrae, 1992b, Eysenck and Eysenck 1985). The same 
holds for the second SSP factor that was earlier conceptualised as Extraversion, 
and combines Adventure Seeking with Impulsiveness (Gustavsson, 2000, 
Schalling et al., 1987). The third SSP factor, Aggression, joins tendencies to act 
aggressively with irritability and unfriendly attitudes, and thus resembles 
Eysenck's Psychoticism (Eysenck and Eysenck 1976). This is in line with other 
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studies confirming that readiness to express aggression and hostile attitudes 
form a separate personality dimension (Zuckerman et al., 1991; Zuckerman et 
al., 1993). 
The relationships of the SSP factors with basic personality dimensions were 
also confirmed by the correlations with the NEO-PI-R scales. Overall, the 
relationships with the five-factor model were in the expected direction. Scales 
belonging to the SSP Neuroticism factor had the strongest correlations with the 
NEO-PI-R Neuroticism scale, confirming that they assess a tendency to 
experience negative emotions, especially anxiety. Impulsiveness and Adventure 
Seeking were joined in the same factor and had somewhat similar correlates of 
NEO-PI dimensions. Both were related to Extraversion but Adventure Seeking 
was also connected to Openness. This suggests that the need for change and 
action is related to curiosity and openness to ideas. It has been demonstrated 
that NEO-PI Openness is related to sensation seeking (García et al., 2005), 
which is analogous to the SSP Adventure Seeking. The SSP Impulsiveness 
deserves closer inspection. Impulsivity is a construct that has been positioned 
differently in the structure of personality. In the five-factor model, it has been 
placed in the Neuroticism domain (Costa and McCrae, 1992b), while 
Zuckerman et al. (1991) considered Impulsiveness the closest to sensation 
seeking and distinct from Neuroticism. Our results show that the SSP Impul-
siveness had the strongest association with the low Deliberation of Con-
scientiousness domain. Similarly, a previous study of health-related personality 
traits found a relationship between the SSP Impulsiveness items and the 
Conscientiousness construct (Gustavsson et al., 2003). This indicates that from 
several aspects of impulsivity, the SSP Impulsiveness measures a lack of 
premeditation, i.e. a tendency to act on the spur of the moment and without con-
sidering the consequences. Like the SSP, most existing impulsivity measures 
assess lack of premeditation, which has been associated with NEO-PI-R low 
Deliberation (Whiteside and Lynam, 2001). This aspect of impulsivity is also 
related to several forms of psychopathology and is closest to Dickman’s concept 
of dysfunctional impulsivity (Dickman, 1990). These results might give a new 
perspective to the SSP factor combining Impulsiveness with Adventure 
Seeking. Often in KSP and SSP studies, this factor has been regarded as 
reflecting the extraversion construct (Gustavsson et al., 2000; Schalling et al., 
1987), but present results suggest that the psychological core of it could be a 
lack of constraint or disinhibition rather than sociability and energy. Clark and 
Watson (Clark and Watson, 1999) have argued that disinhibition versus 
constraint is the third general temperament factor besides negative 
emotionality/neuroticism and positive emotionality/extraversion. Further studies 
are needed to confirm whether the combination of non-planning impulsivity and 
adventurousness reflects extraversion or disinhibition, but the latter could be in 
better agreement with the aim of the SSP in assessing traits constituting 
vulnerability to psychiatric disorders. 
The SSP aggression scales are associated with the NEO-PI-R low Agree-
ableness and high Neuroticism. In the five-factor model, aggression belongs to 
36 
several dimensions, such as Neuroticism that contains the Angry hostility facet, 
and Agreeableness, concerning the Compliance facet in particular (Costa and 
McCrae, 1992). Our results are in accordance with Martin et al. (2000) showing 
that the behavioural, affective and cognitive components of aggression have 
different NEO-PI-R correlates. Our study supports the idea that the tendency 
towards aggressiveness constitutes a separate general personality dimension. At 
least when considering personality traits related to psychopathology, it seems 
appropriate to treat aggressiveness as a separate construct. Overall, the 
relationships between the NEO-PI-R and the SSP confirm the validity of the 
latter instrument. The discrepancies between the two instruments may result 
from the fact that the SSP has more specific orientation than the NEO-PI-R. 
While SSP tries to capture nuances of character pathology, such as different 
types of aggression and anxiety, the NEO-PI-R aims to give a comprehensive 
assessment of normal personality traits. 
A limitation of the study should be addressed. Our study did not include 
randomly selected population sample like the Swedish study, but instead 
consisted of healthy research volunteers and a convenience sample. It has been 
argued that volunteers in research projects cannot be considered a normative 
sample because of the high rate of psychopathology among them (Shtasel et al., 
1991). We tried to correct that possible bias by using a structured diagnostic 




6.2. Study II: Evaluation of personality  
traits in PD using SSP 
6.2.1. Demographic and clinical characteristics 
There were no significant differences between patient and control groups in age 
and sex distribution or in other demographic characteristics, including 
educational level, marriage and occupational status, however more smoked 
cigarettes per day were reported by patients as compared to controls (Table 4). 
None of demographic variables significantly differed between “PD only” and 
“PD comorbid” groups. Both patient groups had similar mean age of onset of 
PD (p=0.49) and similar proportions of those with or without agoraphobia 
(p=0.26), with current panic symptoms or in remission (p=0.67) or of those with 
or without somatic comorbidity (p=0.50). However patients with comorbid PD 
had a higher load of family history of psychiatric disorders than “PD only” 
group (51.3% vs. 33.8%, respectively; p=0.019), and more smokers were found 




Table 4. Demographic characteristics of patient and control groups 
Characteristics  PD patients Healthy subjects Statistics 
Females 148 (76.7%) 220 (70.1%)  
Males 45 (23.3%) 94 (29.9%) χ2=2.63, p=0.11 
Mean age 36.9±12.3 38.9±13.8 F=2.83; p=0.09 
Education  13.8±2.9 14.1±2.9 F=1.29; p=0.26 
Married or common-law 130 (67.4%) 209 (66.6%) χ2=0.03, p=0.85 
Employed or student  146 (75.7%) 249 (79.3%) χ2=0.93, p=0.34 
Smokers 70 (36.3%) 109 (34.7%) χ2=0.13, p=0.72 
Cigarettes per day 5.4±8.2 3.7±6.6 F=5.63; p=0.02 
 
 
6.2.2. Personality differences between total PD group and  
healthy controls 
The analysis of SSP assessments revealed robust differences in personality traits 
between patients with PD and healthy controls (Table 5). All traits, except for 
Detachment and Physical Trait Aggression, were significantly deviated in PD 
group, with the scores for Adventure Seeking and Social Desirability being 
lower, and all the others being higher in patient group. The SSP factors of 
Neuroticism and Aggressiveness, but not Extraversion, were significantly 
higher in PD group than in controls (Table 5). In multivariate logistic regression 
analyses, Somatic Trait Anxiety, Stress Susceptibility, Lack of Assertiveness 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.2.3. Personality traits in patients with pure and comorbid PD 
Comparison of comorbid PD and healthy controls showed significant differences 
in all SSP traits, except of Adventure Seeking; all traits, apart from Social 
Desirability with lower scores, were more expressed in comorbid PD group. 
Neuroticism and Aggressiveness, but not Extraversion showed significant 
differences between the groups (Table 5). Multivariate regression analyses in PD 
comorbid group showed significant differences remaining for Somatic Trait 
Anxiety, Stress Susceptibility and Lack of Assertiveness (Table 6). Patients 
with pure PD were characterized by increased anxiety-related traits, Stress 
Susceptibility, Irritability, and lower Social Desirability, whereas the scores for 
other traits did not significantly differ from those in controls. Additionally, the 
patients with PD only, demonstrated higher Neuroticism and Aggressiveness, 
but similar Extraversion, as compared to healthy subjects (Table 5). In multi-
variate analyses only Somatic Trait Anxiety remained significant for the group 
of PD only (Table 6). The comparison of the two PD groups showed that Anxiety 
Traits, Stress Susceptibility, Embitterment and Irritability were significantly 
more pronounced in patients with comorbid PD than in those with PD only, with 
no significant differences in other SSP traits. In respect to SSP factors, only 
Neuroticism significantly differed between these two PD groups (Table 5). 
 
 
6.2.4. Associations of clinical and demographic factors  
with the personality 
The patients with current PD had significantly higher scores for anxiety traits 
and Stress Susceptibility, but not for any other SSP traits, than PD patients in 
remission. Accordingly, only Neuroticism was significantly higher in patients 
with current PD (p=0.0002) as compared to the remitters. Patients with current 
PD showed significant differences from healthy controls on several SSP 
subscales, except Impulsiveness, Detachment and Physical Trait Aggression. On 
the other hand, patients with PD in remission reported six SSP subscales as 
similar to controls, including the same three as the patients with current PD, 
plus Lack of Assertiveness, Adventure Seeking and Mistrust. Nevertheless, both 
remitters and currently symptomatic patients demonstrated significantly higher 
Neuroticism and Aggressiveness as compared to healthy subjects (data are not 
shown). Comparisons of patients with earlier and later onset of PD or patients 
with and without family history of psychiatric disorders showed no significant 
differences on any SSP subscales or factors (data are not shown). Only Trait 
Irritability was significantly higher in PD with agoraphobia as compared to PD 
without agoraphobia (p=0.0028). In pure PD group no significant differences in 
SSP traits emerged between patients with and without agoraphobia. Although 
all three SSP factors showed higher scores in PD with agoraphobia, only 
Aggressiveness withstood Bonferroni correction (p=0.02 for Neuroticism, 
p=0.04 for Extraversion and p=0.0028 for Aggressiveness). SSP scores in PD 
group were not associated with gender, somatic morbidity, marital or occu-
pational status (data are not shown). 
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6.2.5. Correlation data 
The correlations between individual SSP traits and four variables, including 
age, onset of PD, education and number of smoked cigarettes per day, were 
examined in PD group. The analyses revealed modest, but significant corre-
lations between age of patients and social desirability (r=0.18; p=0.01), onset of 
PD and Verbal Trait Aggression (r=–0.19; p=0.01), educational level and 
Embitterment (r=–0.20; p=0.006) and Mistrust (r=–0.21; p=0.005), and between 
smoking and Somatic Trait Anxiety (r=0.16; p=0.03) and Physical Trait 
Aggression (r=0.17; p=0.025). In addition, several correlations were observed 
for SSP factors (Table 4). In particular, Neuroticism was negatively correlated 
with years of education in PD group and in all studied subjects. In all subjects a 
positive correlation was seen between Neuroticism and numbers of smoked 
cigarettes per day. Extraversion was negatively correlated with age in control 
and total group, but not in PD sample. There were significant correlations 
between Aggressiveness and age as well as onset of PD and number of 
cigarettes in PD group. Aggressiveness was negatively correlated with age in 
both control and total group as well as positively correlated with number of 
smoked cigarettes in total sample of subjects (Table 7). 
 
Table 7. Correlation analyses of SSP factors in patient and control groups 
 Neuroticism Extraversion Aggressiveness 
PD group (n=193)    
Age (years) r=–0.32; p=0.66 r=0.01; p=0.86 r=–0.16; p=0.03 
Onset of PD (years) r=–0.03; p=0.73 r=–0.04; p=0.60 r=–0.15; p=0.04 
Education (years) r=0.16; p=0.03 r=0.01; p=0.91 r=–0.03; p=0.72 
Cigarettes (N) r=0.09; p=0.24 r=0.02; p=0.81 r=0.18; p=0.01 
Control group (n=314)    
Age (years) r=0.05; p=0.43 r=–0.18; p=0.001 r=–0.23; p=0.000 
Education (years) r=0.10; p=0.08 r=0.02; p=0.79 r=–0.08; p=0.17 
Cigarettes (N) r=0.01; p=0.80 r=–0.01; p=0.86 r=0.11; p=0.06 
All subjects (n=507)    
Age (years) r=–0.03; p=0.46 r=–0.11; p=0.01 r=–0.21; p=0.000 
Education (years) r=–0.13; p=0.004 r=0.01; p=0.77 r=–0.07; p=0.11 




We presented the first study using SSP to show significant differences in the 
self-reported personality traits of patients with PD as compared to healthy 
subjects. Earlier, higher Neuroticism and probably lower Extraversion were 
found in patients with PD who were assessed with NEO or Maudsley Perso-
nality Inventory scales, whereas other personality traits were reported to be 
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similar to those in healthy subjects (Bienvenu et al., 2001a, Bienvenu et al., 
2004, Carrera et al., 2006, Freire et al., 2007). As a personality pattern of PD 
patients has been characterised by higher rates of pathological personality traits 
compared to controls, our results showed a deviation of practically all SSP traits 
in patients with PD. We demonstrated that Neuroticism was the main personality 
characteristic of patients with PD, which was in a line with previous reports 
(Bienvenu et al., 2005, Freire et al., 2007, Zugliani et al., 2017). In particular, 
increased Somatic and Psychic Trait Anxiety and Stress Susceptibility were 
observed in all PD groups regardless of clinical status or phenotypes. By 
considering all personality traits simultaneously, Somatic Trait Anxiety stood 
out as the strongest predictor of the presence of PD. The SSP Somatic Trait 
Anxiety indicates a tendency to experience autonomic arousal; therefore, our 
findings are in line with the later developments of the tripartite model showing a 
specific link between heightened arousal and PD (Brown et al., 1998, Clark et 
al., 1994) as well as with the cognitive model of PD, which emphasises the role 
of increased interoceptive sensitivity and misinterpretation of somatic 
symptoms (Clark, 1986) along with the corresponding importance of anxiety 
sensitivity as a trait underlying the tendency for catastrophic misinterpretations 
of bodily changes (McNally, 2002). 
Notably, the degree of Neuroticism correlated negatively with education 
level in both the PD group and the total sample of studied subjects, indicating 
that lower education may contribute to higher neurotic behaviour. One of the 
new findings was the significantly higher Aggressiveness among PD patients as 
compared to healthy subjects. Furthermore, the increased Aggressiveness was 
seen in both pure and comorbid PD groups, but it was more pronounced in the 
comorbid group, suggesting that aggression-related traits in PD may be 
associated with affective comorbidity. Another factor related to Aggressiveness 
in our sample was the presence of agoraphobia. Interestingly, PD patients with 
agoraphobia showed significantly higher Aggressiveness and particularly 
increased Trait Irritability than patients without agoraphobia. This finding 
suggests a link between the psychopathology of agoraphobia and trait Aggres-
siveness, which requires further research. In contrast to some of the previous 
studies, we found no difference in Extraversion between any of the studied PD 
groups and controls, suggesting that this personality aspect is probably less 
affected in PD. 
Previous studies have proposed an accentuation of some personality traits, 
including Harm Avoidance, Neuroticism and Extraversion, in PD patients with 
affective comorbidity as compared with those experiencing pure PD (Ampollini 
et al., 1997, Bienvenu et al., 2001b, Freire et al., 2007). Similarly, Cuijpers et al. 
(2005) found Neuroticism to be the trait most strongly related to comorbidity. In 
our study, practically all SSP subscale scores were higher in patients with 
comorbid compared to pure PD. However, among SSP factors, only Neuro-
ticism was higher among patients with comorbid panic phenotype. A number of 
clinical and demographic variables in our study were similar between PD only 
and comorbid groups, except the higher number of subjects with family 
psychiatric history among patients with affective comorbidity. Nevertheless, 
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none of the SSP traits or factors was significantly related to family psychiatric 
history. Thus, it is unlikely that increased Neuroticism in the comorbid PD 
group could be explained by these factors. 
We also examined the relationships of personality traits to several demo-
graphic and clinical characteristics. The patients with current PD showed higher 
Neuroticism and related traits than PD patients in remission, but they did not 
differ in any other SSP trait or factor. Bienvenu et al. (2004) had also detected 
higher Neuroticism in patients with current PD compared to those in remission. 
Although high Neuroticism was proposed to predict the later onset of anxiety 
disorders (Bienvenu, 2007), none of the SSP personality traits significantly 
differed between patients with the earlier (<30 years) and late (>29 years) onset 
of PD in our sample. Previous studies have found that low Extraversion and low 
trust were associated with both agoraphobia and social phobia, but not with 
depression (Bienvenu et al., 2001a, Bienvenu et al., 2001b, Bienvenu et al., 
2004). Furthermore, Carrera et al. (2006) have shown that PD patients were only 
more introverted than controls in the presence of agoraphobia. However, higher 
Neuroticism in patients with PD was prominent irrespective of agoraphobia. 
Furthermore, Openness, Agreeableness and Conscientiousness were unrelated 
to agoraphobia in their study. In our data set, neither Extraversion nor Neuro-
ticism was related to agoraphobia. In respect to gender effects, Foot and Koszycki 
(2004), using NEO-PI-R, showed a lack of significant differences in anxiety 
sensitivity and Neuroticism scores between female and male PD patients with or 
without agoraphobia. However, women scored higher than men on Extraversion 
and men on angry hostility and depression facets of Neuroticism. In our study, 
none of the SSP traits was significantly affected by gender. 
To the best of our knowledge, the sample of patients with PD in our study 
was to date the largest among the studies investigating personality traits in PD. 
However, certain limitations should be considered when interpreting our results. 
We were unable to account for the effects of treatment on personality traits in 
our sample. Notably, neither clinical severity nor short-term treatment response 
in PD was influenced by personality factors in an earlier study by Carrera et al. 
(2006). Both our findings and previous findings indicate that the expression of 
anxiety and stress-related traits may be state-dependent and intensified in the 
symptomatic stage of PD. We did not use specific clinical scales for the assess-
ment of anxiety and panic severity. Although current PD would evidently be 
associated with more severe symptoms than PD in remission, the correlations 
between clinical and personality assessments should be addressed in more detail 
in the future. A possible confounder in our study was the small proportion of 
patients who met diagnostic criteria for bipolar disorder or (hypo)manic episode. 
Although this subgroup demonstrated personality traits consistent with non-
bipolar groups (data not shown), the specific characteristics of PD with bipolar 




6.3. Study III: Association between personality traits and 
escitalopram treatment efficacy in PD 
6.3.1. Demographic and clinical characteristics 
In present study, out of the 107 patients, who completed the study, 38 were 
diagnosed with PD (36%), 24 with PD and agoraphobia (22%), 14 with PD and 
co-morbid mild depression (13%) and 31 with PD, agoraphobia and mild 
depression (29%). The demographic characteristics of these groups did not differ 
significantly (Table 8). All 107 patients had a PDSS score higher than 7. At the 
beginning of the study, the mean score of PDSS was 16.07 and by the end of the 
study 5.16. By the end of study eighty-four (79%) patients met the criteria of 
remission. 
 
Table 8. Demographic and clinical data 
Variable Mean or Frequency (n) SD or % 
Age (years; mean, sd) 34 11,73 
Education (years; mean, sd) 13,7 2,5 
Duration of PD (years; mean, sd) 7,7 9,5 
Comorbid somatic diseases (n, %) 37 26 
Gender (n, %)   
Male 36 34 
Female 71 66 
Occupation (n, %)   
Employed 70 67 
Student 14 13 
Retired 2 2 
Unemployed 17 16 
Disability 1 1 
Smoking (n, %)   
Never 54 52 
Formerly 22 21 
Currently 28 27 
Alcohol (n, %)   
Does not use 22 21 
Once a month 39 38 
2–4 times a month 35 34 
2–3 times a week 8 8 
Diagnoses (n, %)   
PD 38 36 
PD and agoraphobia 24 22 
PD and mild depression 14 13 
PD, agoraphobia, and mild depression 31 29 
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6.3.2. Changes in SSP sub-scale scores following escitalopram 
treatment in PD 
The means of all the T-scores of SSP sub-scales express tendency to decrease 
during the study. The largest changes were in Somatic Trait Anxiety  
(–6.59±9.98), Stress Susceptibility (–5.22±9.55), and Psychic Trait Anxiety  
(–5.13±8.18). The rest of the means of the scores of SSP sub-scales decreased 
less (Table 9). 
 
Table 9. SSP sub-scale scores at visit 0 and visit 6, and the change of the scores 
















































































































6.3.3. Correlation data 
None of the baseline scores of SSP sub-scales was strongly associated with the 
treatment response. Only the Impulsiveness score was weakly correlated with 
the change of PDSS (r=0.22, p=0.033), and it helped to predict the odds for 
remission OR=0.90, p=0.005); however, these findings were statistically not 
significant after the adjustment for multiple comparisons (Table 10).  
 
Table 10. Correlations between baseline scores of SSP sub-scales and change in PDSS 
and ratios of the odds of remission 
SSP sub-scale r (95% CI) P OR* (95% CI) p 
Somatic Trait Anxiety 0.05 (–0.16...0.24) 0.675 1.02 (0.93…1.03) 0.697 
Psychic Trait Anxiety –0.04 (–0.23...0.18) 0.818 1.00 (0.95…1.05) 0.928 
Stress Susceptibility 0.04 (–0.16...0.24) 0.692 0.98 (0.96…1.05) 0.623 
Lack of Assertiveness 0.01 (–0.18...0.23) 0.810 1.05 (0.95…1.04) 0.240 
Impulsiveness 0.22 (0.03...0.41) 0.033 0.90 (0.88…0.97) 0.005 
Adventure Seeking –0.01 (–0.22...0.19) 0.895 1.02 (0.97…1.06) 0.590 
Detachment –0.03 (–0.24...0.16) 0.692 1.02 (0.97…1.06) 0.572 
Social Desirability –0.05 (–0.23...0.17) 0.766 1.04 (0.97…1.07) 0.254 
Embitterment 0.00 (–0.18...0.23) 0.818 0.96 (0.91…1.00) 0.239 
Trait Irritability 0.13 (–0.05...0.35) 0.142 0.94 (0.90…1.00) 0.152 
Mistrust 0.09 (–0.11...0.29) 0.401 0.98 (0.91…0.99) 0.521 
Verbal Trait Aggression 0.09 (–0.07...0.32) 0.222 1.00 (0.94…1.04) 0.898 
Physical Trait Aggression 0.20 (–0.01...0.38) 0.064 1.00 (0.97…1.06) 0.999 
* Adjusted for sex, age, years of education, level of drinking frequency, presence of somatic co-
morbidities, and for the presence of mild depression and/or agoraphobia. The remission was 
defined if the score on the CGI improvement scale was 2 or less, the PDSS score 7 or less and no 
panic attacks had occurred for at least last two weeks. 
 
Some weak correlations existed between the changes of the scores of SSP sub-
scales and the changes in the clinical assessment scores. The change of SSP 
Stress Susceptibility was weakly correlated with the change of CGI-S (r=–0.27); 
the change of SSP Lack of Assertiveness was weakly correlated with the change 
of HAM-A (r=0.32) and EST-Q depression (r=0.21). However, none of the 
partial correlation coefficients was statistically significant after Holm-Bonferroni 
correction. (Table 11). The baseline scores of SSP sub-scales and the change in 
EST-Q depression score were not correlated. Similarly, neither changes in CGI-
S scores nor changes in HAM-A scores were correlated with the baseline scores 
of SSP sub-scales. Partial correlations between Impulsiveness and change in 
CGI-S (r=0.29) and change in HAM-A (r=0.28) were statistically not 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Several personality traits on the SSP measurement, including Embitterment, 
Impulsiveness, Lack of Assertiveness, Psychic and Somatic Trait Anxiety, and 
Stress Susceptibility, improved after 12 weeks of medication in comparison with 
the baseline scores. Although the changes in the SSP scores after the treatment 
period were generally more pronounced among remitters to escitalopram treat-
ment compared to non-remitters, none of scores of the SSP significantly 
differed between these groups at the end of the treatment period. Moreover, no 
significant correlations were found between the changes of scores of SSP sub-
scales and the changes of clinical assessment scores following 12 weeks of 
medication. These results look quite intriguing in the light of our previous study, 
which demonstrated the maladaptive personality disposition of practically all SSP 
traits in patients with PD (Võhma et al., 2010, Study II), confirming that 
maladaptive trait patterns may contribute to the development and expressions of 
PD. The current study suggests that antidepressant medication is accompanied 
by certain improvement in personality patterns in patients with PD, but changes in 
the traits do not seem to be clearly associated with treatment efficacy. Although 
our results may confirm the trait rather than state phenomena of personality 
deviations in PD, it is possible to speculate that personality characteristics are 
more flexible in terms of normalisation, at least among good responders to 
pharmacological intervention. The effect of antidepressant medication on perso-
nality traits in PD has not been univocally proven. None of the personality traits 
assessed by the Neuroticism-Extraversion-Openness Five-factor Personality 
Inventory was related to the short-term response to SSRI treatment in PD 
(Carrera et al., 2006). Still, a significant decrease was observed in all anxiety 
related traits after 6 months of treatment with SSRI citalopram in a smaller 
sample of PD patients, using the original scale for SSP measurement, the KSP 
(Neuger et al., 2002). Considering that a similar tendency to decrease SSP 
scores was found among our patients, we may suggest that a longer treatment 
period would probably reveal a statistically stronger effect of medication on 
personality traits. However, the more pragmatic explanation would be that the 
response to antidepressant medication and particularly the substantial decrease 
in clinical severity could also improve the self-rating of one’s own personality 
characteristics. 
The second main goal of our study was to detect the possible predictive 
effect of personality traits on treatment response to antidepressant medication. 
The only positive finding we detected, but which did not withstand Bonferroni 
correction for multiple comparisons, was the predictive effect of impulsivity. 
PD non-remitters to 12-week treatment with escitalopram showed a higher 
Impulsivity score at baseline SSP assessment compared with responders. SSP 
Impulsivity correlates with several constructs of the five-factor personality model. 
The strongest associations have been found with the Impulsiveness facet of 
Neuroticism and the Deliberation facet of Conscientiousness, thereby combining 
a low frustration tolerance with non-planning impulsivity (Aluoja et al., 2009). 
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Lower Neuroticism has predicted clinical improvement at three-month point in 
a Collaborative Care for Anxiety and Panic Study study (Chavira et al., 2009). 
The predictive effect of Impulsivity in our study was also confirmed by 
correlation analyses between SSP and the clinical scales scores. In particular, 
the higher score of Impulsivity at baseline was close-to-significantly associated 
with a lesser decrease in the CGI severity score during the treatment period. The 
same trends were also seen on the PDSS and HAM-A scales, but correlations 
did not reach statistically significant levels. Previously we reported that PD 
phenotype is characterised by a higher Impulsivity in comparison to normal 
presentation (Võhma et al., 2010, publication II). Nevertheless, the relationship 
between anxiety and impulsivity seems controversial (Barratt 1965; Askenazy et 
al., 2000). Our study accords with Marchesi et al. (2006) in finding that features 
of borderline personality disorder predicted a lower likelihood of remission with 
SSRIs in PD patients. Emotional instability and low impulse control are 
characteristic features of borderline personality, and they are also part of the 
Impulsivity construct measured by the SSP. Studies conducted with different 
methodologies have found no correlation between anxiety and impulsivity 
(Askenazy et al., 2000; Apter et al., 1993; Lecrubier et al., 1995; Caci et al., 
1998). On the other hand, in several studies anxiety disorder patients have 
reported higher scores of impulsivity than healthy controls (Summerfeldt et 
al.,2004; Del Carlo et al., 2012). The possible involvement of impulsivity in 
treatment response appears to be less understood. Silva et al. (2010) demon-
strated that borderline personality disorder carriers of long alleles of serotonin 
transporter promoter region related polymorphism (5-HTTLPR) had a better 
anti-impulsive response to SSRI fluoxetine treatment than in patients with short 
alleles. Walderhaug et al. (2010) also showed that reduced serotoninergic 
neurotransmission following acute tryptophan depletion increased impulsivity 
in healthy men, but decreased it in women. Considering that the relationship 
between reduced function of the central serotonin system and impulsivity is 
well recognised (Brown et al., 1979; Brown et al., 1982; Coccaro et al., 1989; 
O’Keane et al., 1992), we suggest that an increased impulsivity and worse anti-
panic response to escitalopram treatment may indicate a more pronounced or 
persistent serotoninergic dysfunction, at least in the sub-group of patients with 
poor treatment outcome. Interestingly, significant and persistent changes in 
central serotonin functioning were observed by neuroimaging studies in male 
patients with PD (Maron et al., 2010b; Nash et al., 2008; Cannon et al., 2013). 
Nevertheless, none of these brain-imaging studies had measured the expression 
of the Impulsivity trait among their sample. 
To the best of our knowledge, the sample of patients with PD in our study 
was to date the largest among the studies investigating the relationship between 
personality traits and treatment response in PD. However, certain limitations 
should be taken into account when interpreting our results. All patients were 
treated in a naturalistic way using an open-label drug, so placebo responses 
cannot be excluded; the control group is absent. However, to diminish possible 
sources of bias in variation in clinical assessments, the severity of PD symptoms 
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and treatment response were carefully rated by one experienced psychiatrist at 
each visit. Furthermore, all clinical assessments on the patients’ self-reports on 
SSP measurements were made blindly. However, our sample size can still be 
considered not large enough to reveal statistically significant findings, 




7. GENERAL DISSCUSSION 
According to our results, the Estonian version of the SSP has demonstrated high 
reliability and validity as evaluated in reference to both: the Swedish original 
data and the position of the SSP-measured traits within the basic personality 
dimensions of the five-factor model. Since the first introduction of SSP 
(Gustavsson et al., 2000), this scale has been applied in various mental health 
and somatic disorders, including depression, schizophrenia, bipolar disorder, 
cognitive disturbances, eating problems, psoriasis and others (Aluoa et al., 
2018; Iliadis et al., 2015; Ausén et al., 2011, Elfhag 2005; Fagerberg et al., 
2018; Rasul et al., 2016; Remröd et al., 2015; Sparding et al., 2017; Volgsten et 
al., 2010). The initial idea of developing KSP and its later modification with 
improved psychometric qualities, SSP, was to attain an instrument for 
evaluating personality traits in psychopathological groups. This was also the 
main reason for adaption of the Estonian version of SSP for several purposes, 
including the personality assessment in research and a clinical context. The SSP 
appears to be fairly stable in terms of repeated measures within the same 
individual groups (Hedman et al., 2014, Muller et al., 2015), and has shown 
similar factor loadings in different samples (Gustavsson et al., 2000, Fagerber et 
al., 2016, Volgsten H et al., 2010). The other advantage is its relatively short 
format, consisting of 91 items, as compared to 238–240 items for the full NEO 
and TCI questionnaires, which is an argument in favour of time effectiveness for 
SSP. Thus in line with earlier studies, the current work gives additional strong 
support for recommending the extensive use of SSP in further exploration of the 
role of personality factors in mental disorders. 
It should be noted that the current work is the first implementation of SSP in 
investigation of personality traits in PD, which is very important in that the 
relationship between personality traits and PD is significantly less explored than 
the association of PD with personality disorders. We found that virtually all SSP 
traits show an abnormal range in patients with PD, while at least some 
personality aberrations seem to be more pronounced in PD with affective 
comorbidity compared to pure PD. Generally, the SSP factors of Neuroticism 
and Aggressiveness, but not Extraversion, were significantly higher in the PD 
group than in controls, and only a few demographic and clinical variables were 
associated with SSP scores in PD patients. These results add to the evidence of 
a maladaptive personality disposition in patients with PD, particularly high 
Neuroticism and manifest Somatic Trait Anxiety, which are probably not 
influenced by other clinically relevant factors. The associations between PD and 
both higher Neuroticism as well as lower Extraversion are in line with similar 
earlier observations (Bienvenu et al., 2001b, Bienvenu et al., 2004, Carrera et 
al., 2006, Freire et al., 2007). However, the finding of higher Aggressiveness and 
increased Trait irritability among PD patients, particularly with agoraphobia, as 
compared to healthy subjects seems very intriguing. In our previous study, we 
examined how personality disposition as assessed with SSP may affect the 
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response to the cholecystokinin tetrapeptide (CCK-4; 50 microg) challenge in 
healthy volunteers (n=105). Our results showed that the occurrence of CCK-4-
induced panic attacks was best predicted by adhering to SSP-defined traits: 
Lack of Assertiveness, Detachment, Embitterment and Verbal Aggression. More-
over, for different subsets of CCK-4-induced symptoms, the traits of Physical 
Aggression, Irritability, Somatic Anxiety and Stress Susceptibility also appeared 
related to panic manifestations. In particular, higher Verbal trait Aggression 
predicted the occurrence of a panic attack, whereas increased Physical Trait 
Aggression predicted all aspects of panic symptoms (Toru et al., 2010). 
Previously, it has also been indicated that the tendency to be verbally aggressive 
was associated with a panic response to pentagastrin administration (Radu et al., 
2003). The association between Aggressiveness and provoked panic response is 
further supported by George et al. (2000), who showed that persons exhibiting a 
high rate of physical aggression in domestic relationships react with more panic 
symptoms to sodium lactate provocation. The exact nature of these associations 
is unclear. A Radu et al. (2003) finding that personality emerges as a significant 
predictor of panic reaction only with a lower dose of pentagastrin suggests a 
rather non-specific stress reactivity. It is possible that certain personality traits 
heighten an individual’s reactivity to different kinds of stressors, including 
panic-provoking agents. On the other hand, anxiety and aggression are known 
to share underlying neurobiology, including aspects of CCK neurotransmission 
and pharmacotherapy approaches (Siegel et al., 2007). Thus, our observation 
that Aggressiveness predisposes to a greater panic reaction in a laboratory 
challenge in healthy volunteers may indicate one relationship between traits of 
aggression and susceptibility to panic attacks. However, the relevance of these 
findings to clinical aspects of PD is not fully clear. Although an earlier study 
found that patients with PD reported significantly greater levels of anger 
aggression compared to controls (Moscovitch et al., 2008), this was not 
confirmed by other research showing a non-significant relationship between PD 
and aggression (Niazi et al., 2008). Interestingly, neither Physical nor Verbal 
traits of Aggression changed throughout the 12-week treatment with escitalopram 
in the current study, suggesting that aggressiveness is probably one of the 
endophenotypic features of PD. 
Although several other personality traits, including Embitterment, Impul-
siveness, Lack of Assertiveness, Psychic and Somatic Trait Anxiety and Stress 
Susceptibility, have improved on the SSP measurement after 12 weeks treat-
ment with escitalopram, none of these positive changes significantly differed 
between remitters and non-remitters at the end of the treatment period. 
Furthermore, the lack of correlations between the changes in personality traits 
and the changes of clinical assessment scores following escitalopram treatment 
indicates that improvement in personality characteristics is probably contributed 
by the general effect of recovery resulting in better self-perception. Considering 
the earlier suggestion that the result of therapy can be attributed to the state 
level variance in personality trait measures (Du et al., 2002; Marchevsky, 1999), 
it would be tentative to speculate that SSP improvement following a treatment 
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period in PD can be temporally and may depend on the disease course. 
However, the recent meta-analysis conducted by Roberts et al. (2017) based on 
data from published studies in 1959–2013 and involving over 20,000 partici-
pants demonstrated that in comparison with other disorders such as depression, 
eating disorders, personality disorders and substance use, patients with anxiety 
disorders reported more pronounced and long-lasting changes in personality 
characteristics, especially in Neuroticism and Extraversion, just after a few 
weeks of therapy. In additional, a brief internet-based cognitive behaviour 
therapy (12 weeks) for severe health anxiety causes long-term changes in 
measures of SSP personality traits related to Neuroticism, whereas Extraversion 
and Aggression remained largely unchanged (Hedman et al., 2014). Interestingly, 
the stability of the SSP personality trait was also reasonably high among 
patients with psychotic disorders, although lower than among non-psychotic 
individuals in the study of Fagerberg (2018). On the other hand, Roberts et al. 
(2017) concluded by meta-analysis of earlier studies that psychopharmaco-
logical therapies actually exhibited a slightly smaller effect than the other treat-
ment approaches, e.g. CBT, supportive therapy and psychodynamic methods, 
on changes of personality traits. This observation looks very intriguing in terms 
of further exploration of non-pharmacological therapy methods and their 
influence on SSP personality traits in PD patients. 
The other dilemma raised from this study is the predictive effect of perso-
nality traits on treatment response to antidepressant medication in PD. The only 
personality trait that shows the possible predictive effect in current study was 
Impulsivity. In particular, a higher Impulsivity score at baseline SSP measure-
ment in PD patients was associated with poor treatment outcome; however, no 
other SSP personality characteristics demonstrated a predictive effect. These 
results are in accordance with our recent study aiming to identify specific 
personality traits that could predict the treatment response and/or the dynamics 
of symptom change in 132 outpatients with major depressive disorders, who 
were also treated with escitalopram antidepressants for 12 weeks. We found that 
none of the studied SSP traits predicted the end result of the treatment. 
However, patients with higher Social Desirability, lower Stress Susceptibility 
and lower Irritability achieved a more rapid decrease in depression symptoms. 
Nevertheless, the latter associations did not survive the multiple testing cor-
rections, probably due to the relatively small sample (Aluoja et al., 2018). 
Therefore, these findings suggest that specific personality traits may predict the 
trajectory of symptom change rather than the overall improvement rate, which 
is probably true for both highly co-existing mental disorders such as PD and 
depression. Notably, the lack of the major influence of SSP personality on the 
disease course was reported in patients with bipolar disorder, indicating that the 
personality profile does not seem to have prognostic value over a 2-year period 
in this type of mood disorder (Sparding et al., 2017). 
Finally, it should be noted that genetic factors, not investigated in this study, 
should be considered when exploring the relationship between PD and personality 
traits. For example, there are recent findings showing that genetic poly-
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morphisms, particularly within hydroxysteroid (11-beta) dehydrogenase 1 gene 
and the serotonin transporter gene-linked polymorphism 5-HTTPLPR, may 
modify manifestation of Neuroticism-related personality traits assessed by SSP 
(Iliadis et al. Gingnell et al., 2010). Although there is strong evidence that 
several genes may have a modulatory role on the onset, course and treatment 
outcome in PD, including among the Estonian population (Maron et al., 2010a), 
the genetic part was not included in this study due to the relatively small sample 
and risk of false findings; however, we recognise that the genetic impact on 




1. We demonstrated that the SSP Estonian version has acceptable psychometric 
properties. The SSP measures traits that seem to be universal and are in line 
with the major theories of personality structure. 
2. The use of SSP proved to add pertinent information on clinically relevant 
personality dimensions in patients with PD. We showed evidence of 
maladaptive trait patterns in patients with PD. In particular, these patients are 
characterised by high Neuroticism and higher manifestation of Somatic Trait 
Anxiety. 
3. More pronounced personality trait deviations were observed in PD with 
affective comorbidity. Aggressiveness, in particular, was associated with 
agoraphobia and affective comorbidity. 
4. Although maladaptive personality disposition in patients with PD shows a 
certain trend towards normalisation after a 12-week treatment with the 
antidepressant escitalopram, there was not a strong correlation with the 
clinical outcome. A better response to medication was accompanied by more 
pronounced improvement in personality characteristics, which is probably 
contributed by the general effect of recovery resulting in more positive self-
perception. 
5. The Impulsiveness shows a possible predictive effect on the antidepressant 
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SUMMARY IN ESTONIAN 
Paanikahäirega patsientide isikuomaduste,  
kliiniliste näitajate seos farmakoloogilise ravivastusega 
Sissejuhatus 
Paanikahäire (PH) kui eraldiseisev häire lisati ametlikult psühhiaatriliste häirete 
nimistusse 1980. aastal DSM III publitseerimisel (APA, 1980). Paanikahäiret 
iseloomustavad korduvad paanikahood ning ootusärevus nende hoogude ees, 
sageli kujuneb sellest välja agorafoobia (DSM-IV, RHK-10). 
Paanikahäire eluaegne esinemissagedus on 1.5–3.5%, kusjuures 12 kuu 
esinemissagedus on naistel kõrgem kui meestel (Klerman jt. 1991). PH algab 
tavaliselt kahekümnendate eluaastate keskel, naistel on leitud kõrgeim haaratus 
25–34 eluaasta vahel, meestel 30–44 eluaasta vahel (Wittchen ja Essau, 1993). 
PH kahjustab tõsiselt sotsiaalset toimimist, töö ja isikliku eluga toimetulekut, 
mõjutades seega oluliselt üldist elukvaliteeti (Candilis jt.1999). PH patsientidel 
on kalduvus tõlgendada kehalisi sümptomeid katastroofilisel moel, seetõttu on 
selle häirega isikute meditsiiniteenuste kasutamine ebaproportsionaalselt kõrge 
(Barsky jt. 1999), võrreldes kontrollvalimiga teevad nad oluliselt sagedamini 
visiite perearsti vastuvõtule (Simpson jt. 1994), kasutavad sagedamini välti-
matut abi ja vaimse tervise abi võrreldes teiste üldmeditsiiniliste ambulatoorsete 
patsientidega (Barsky jt. 1999). PH loetakse üldiselt kroonilise kuluga häireks. 
Pikaaegses uuringus on kolme aasta järel leitud ainult 10% patsiente täielikult 
sümptomivabana (Noyes jt. 1990), täielik remissioon viie aasta pärast on leitud 
vaid 12% PH patsientidest (Faravelli jt. 1995). 
Paanikahäire etiopatogenees on kompleksne, hõlmates sotsiodemograafilisi, 
geneetilisi, bioloogilisi ja psühholoogilisi faktoreid (Andrizano 2012, Wittchen 
ja Essau 1993, Scocco jt. 2007, Faravelli 1995, Tweed jt. 1989; Cougle jt. 2010, 
Goodwin jt. 2005b, Roy-Byrne jt. 1986; Assellmann jt. 2017, Hirshfeld-Becker 
jt. 2008). Paanikahäire ravis on kaksikpimedates uuringutes tõestanud efektiivsust 
viie ravimiklassi preparaadid: selektiivsed serotoniini tagasihaarde inhibiitorid 
(SSTI), serotoniini noradrenaliini tagasihaarde inhibiitorid, tritsüklilised anti-
depressandid, monoamiinioksüdaasi inhibiitorid ning bensodiasepiinid (Mitte, 
2005; Bradwejn, 2005; Otto jt.2001; Gould jt. 1995; Susman &Klee 2005; 
Goddard jt.2001). Avaldatud uuringu kohaselt 20–40% paanikahäirega patsien-
tidest ei anna ravivastust farmakoteraapiale ja 30–40% kognitiiv-käitumuslikule 
psühhoteraapiale (van Apeldoorn jt. 2008), seega mitte kõik patsiendid ei 
saavuta remissiooni. 
SSTI-d leiti Otto (2001) ja kolleegide poolt läbi viidud 12 uuringut hõlmavas 
metaanalüüsis üldistunud ärevushäire ning paanikahoogude sageduse vähenda-
misel platseebost oluliselt efektiivsemad. Ka käesolevas uuringus on kasutatud 
paanikahäire raviks SSTI estsitalopraami 10–20 mg päevas. 
Isiksust on kirjeldatud kui isiku unikaalset psühholoogiliste omaduse kogumit, 
mis väljendub läbi elu erinevates olukordades kindlates käitumismustrites (Gerrig 
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& Zimbardo, 2002). Isiksuse põhijooni on peetud elu jooksul stabiilseks, kuid 
viimastel aastatel on leitud, et need võivad läbi elu siiski muutuda seoses isiksuse 
küpsemisega või elusündmuste mõjul (Seviewright jt. 2002, Cohrs jt. 2008). 
Isiksuse omaduste, eriti neurootilisuse ja ekstravertsuse muutusi, on seostatud 
ka kliinilise sekkumisega (Roberts jt. 2017). On oletatud, et isiksus mängib 
otsustavat rolli paanikahäire alguse ning arengu juures (Clark, Watson, & Ineka, 
1994). Paanikahäirega patsientidel on leitud kõrgenenud neurootilisust ja madalat 
positiivset emotsionaalsust (Bienvenu jt. 2001b; Bienvenu jt. 2004; Carrera jt. 
2006; Zugliani jt. 2017). Madalat ekstravertsust on seostatud agorafoobiaga, mitte 
otseselt paanikahäirega (Bienvenu jt. 2004). Samas on leitud, et kõrgenenud 
neurootilisus ja madal ekstravertsus tulevad esile pigem komorbiidsuse korral 
(Cuijpers jt. 2005; Zugliani jt. 2013). 
Paanikahäire ja isiksuse joonte seoste osas on mitu autorit avaldanud arva-
must, et isiksuse jooni, eriti neurootilisust, võivad mõjutada nii häire ägedad 
sümptomid, farmakoteraapia kui ka kognitiiv-käitumuslik teraapia (Rocca jt. 
2006, Corchs jt. 2008). Võrreldes depressiooniga on ärevushäirete, sealhulgas 
paanikahäire seost isiksuse omadustega vähem uuritud ja mõistetud (Bienvenu 
& Brandes, 2005). Neid seoseid on käsitletud kahepoolsetena, kus isiksus võib 
mõjutada ravitulemust ning ravi võib viia muutustele isiksuse mustris. On 
leitud, et isiksuse kõrvalekalded mõjutavad paanikahäire sümptomaatika inten-
siivust (Sokol jt. 1995, Ozkan jt. 2005) ja võivad negatiivselt mõjutada ravi-
tulemust (Slaap&den Boer 2001; Marchesi jt. 2006). Samas on uuringuid, kus 
ükski NEO-PI-R-ga hinnatud isiksuse joon ei olnud seotud häire kliinilise 
raskuse ega lühiaegse ravitulemusega SSTI-ga (Carrera jt. 2006). Samuti ei leitud 
seost isiksuse joonte ja PH sümptomite remissiooni vahel (Marchesi jt.2006). 
Seega on uuringute tulemused isiksuse joonte mõjust paanikahäire ravitule-
musele jäänud vastuoluliseks. 
Hinnates PH farmakoloogilise ravi mõju isiksusele leiti, et sümptomite 
paranemisel vähenesid oluliselt ka neurootilisusega seotud isiksuse jooned 
(Reich jt. 1991; Noyes jt. 1986, Tang jt 2009, Barlow jt. 2013). 
Kognitiiv-käitumisteraapia tulemusena leiti, et SSP-ga hinnatud neurootilised 
jooned vähenesid, samas ekstravertus ja agressiivsus jäid muutumatuks (Hedman 
jt. 2014). Märkimisväärne on, et kuigi on uuringuid, kus PH remissioon on seotud 
isiksuse joonte osalise “normaliseerumisega” (Brandes jt. 2006), on mitmeid 
uuringuid, kus isiksuse jooned jäävad stabiilseks kogu PH kulus (Morey jt. 




Paanikahäire ja isiksuse seosed ei ole endiselt lõplikult selgitatud, see on jäänud 
teadusliku arutelu ja uurimise teemaks, sealjuures uuringute valimid on olnud 
suhteliselt väikesed ning tulemused vasturääkivad. Ärevushäirete, sealhulgas 
paanikahäire ravitulemust ennustavate tegurite parem tundmine aitab kaasa 
personaalmeditsiinile, patsiendile individuaalselt parima ravi valikuvõimalusele. 
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Isiksusel näib olevat ülioluline roll psüühikahäirete patogeneesis ja prognoosis. 
Oluline on ka see, et isiksuse omadused ravitulemuse ennustajana on kergesti 
hinnatavad. Käesolevas töös on kasutatud isiksuse hindamiseks Rootsi ülikoolide 
isiksuseskaalat (SSP), mille 13 alaskaalat on näidanud häid psühhomeetrilisi 
omadusi Rootsi normpopulatsioonis, kuid mis on eelkõige disainitud mõõtma 
isiksuse jooni psühhopatoloogia esinemisel (Schalling 1978; Gustavsson jt. 
2000). SSP on tõestanud kasulikkust mitmetes psühhobioloogilistes uuringutes 
(Damberg jt. 2003, Jönsson jt. 2003). Faktoranalüüsi alusel mõõdab SSP kolme 
põhifaktorit: neurootilisus, ekstravertsus, agressiivsus (Gustavsson jt. 2000). 
Käesolevas uuringus kontrolliti SSP eestikeelse versiooni reliaablust ning 
valiidsust. See võimaldas hinnata SSP faktorite universaalsust originaalpopulat-





Käesoleva töö üldine eesmärk oli kirjeldada paanikahäirega patsientide isiksuse 
omadusi ja uurida nende isiksuse joonte seoseid ravitulemusega, kasutades 
valideeritud SSP hindamisskaalat. 
 Kitsamad eesmärgid: 
1. Kontrollida eestikeelse SSP reliaablust ja valiidsust (I) 
2. Iseloomustada SSP-ga mõõdetud isiksuse joonte positsiooni 
viiefaktorilise isiksuse- mudeli suhtes (I) 
3. Tuvastada paanikahäirega patsientide ja tervete isikute isiksuse joonte 
erinevused hinnatuna SSP-ga (II) 
4. Uurida isiksuse omaduste erinevusi paanikahäirega patsientidel ilma ja 
koos afektiivse häirega ning jälgida paanikahäirel SSP domeenide 
(alaskaalad, üldfaktorid) ning erinevate demograafiliste ja kliiniliste 
muutujate vahelisi seoseid (II) 
5. Uurida estsitalopraami ravi mõju paanikahäirega patsientide isiksuse 
joontele (III) 
6. Leida, kas SSP-ga mõõdetud isiksuse omadused ennustavad paanikahäire 
farmakoloogilise ravi tulemust 
 
 
Uuringutes osalejad ja meetodid 
I uuringus osales 529 uuritavat. Esimeses grupis oli 331 tervet vabatahtlikku 
erinevatest uuringuprojektidest Tartu Ülikooli Psühhiaatriakliinikus ning teine 
grupp koosnes 198 erineva haridusliku ja sotsiaalse taustaga isikust. Mõlemas 
grupis osalejad täitsid Rootsi ülikoolide isiksuseskaala (SSP) (Gustavsson jt. 
2000) ja 197 isikut teisest grupist täitsid NEO-PI-R (Costa &McRae, 1992b, 
Kallasmaa jt. 2000) eestikeelse variandi. 
II uuringus olid kaasatud 193 paanikahäirega patsienti Tartu Ülikooli Psüh-
hiaatriakliinikust ning 314 ajalehekuulutuse kaudu leitud tervet vabatahtlikku. 
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Paanikahäirega patsientidest 71 olid ainult paanikahäirega, 122 komorbiidse 
paanikahäirega, kusjuures 93-l esines kaasuvana depressioon, 29-l bipolaarne 
häire, 46-l teised ärevushäired, sealhulgas obsessiivne-kompulsiivne häire ja 
sotsiaalfoobia. Agorafoobia esines kaasuvalt 115-l, sealhulgas ainult paanika-
häirega grupis 46-l ja komorbiidse häirega grupis 69-l. Kõik patsiendid ning 
tervete kontrollgrupp täitis SSP eestikeelse variandi. 
III uuringus osales lõplikus valimis 107 paanikahäirega patsienti, kes täitsid 
SSP algvisiidil ning 12-nädalase ravi järel 10–20 mg estsitalopraamiga. Kaasu-
valt täitsid uuritavad algvisiidil ning iga järgneva kahe nädala järel lisaskaalad 
PDSS (Shear jt. 1997), CGI (Guy 1976), HAM-A (Hamilton 1959), emotsio-
naalse enesetunde küsimustiku (EEK-2) (Aluoja jt. 1999), TSES (Vanderkooy 
jt. 2002). 
Kõikides uuringutes tõendati paanikahäire ja teiste häirete olemasolu või 
puudumist kliinilise intervjuu ning rahvusvahelise neuropsühhiaatrilise intervjuu 




Esimeses uuringus olid SSP alaskaaladest naistel oluliselt kõrgemad väärtused 
psüühilisel ärevusel, vastuvõtlikkusel stressile, kehtestavuse puudumisel ja 
sotsiaalsel soovitavusel. Meestel olid kõrgemad näitajad verbaalsel ja füüsilisel 
agressioonil, umbusklikkusel ja seikluste otsimisel. Suurimad soolised erine-
vused ilmnesid agressiooni ja ärevuse alaskaaladel. 
Rootsi ülikoolide isiksuseskaalal (SSP) leiti kolmefaktoriline struktuur. 
Esimene faktor hõlmas skaalasid, mis iseloomustavad neurootilisust, kirjel-
dades ära 27,8% andmete koguhajuvusest. Kõige suurema faktorlaadungiga 
selles faktoris olid somaatiline ja füüsiline ärevus, vastuvõtlikkus stressile, 
kehtestavuse puudumine. 
Teine faktor kirjeldas 20,2% andmete koguhajuvusest. Faktori moodustasid 
alaskaalad verbaalne ja füüsiline agressiivsus, ärrituvus, isoleerumine ja madal 
sotsiaalne soovitavus, osutades agressioonile ja mittekonformsusele. Kusjuures 
isoleeritus ja ärritatavus haakusid ka esimese ja kolmanda faktoriga. 
Kolmas faktor kirjeldas ära 14,8% andmete koguhajuvusest. Kolmandasse 
faktorisse kuulusid impulsiivsus ja seikluste otsimine. 
Umbusklikkus haakus lähedaselt kahe faktoriga, mis mõõtsid neurootilisust 
ning agressiooni. 
Seega faktoranalüüs kinnitas eestikeelse skaala kolmefaktorilist struktuuri 
sarnaselt esialgsele Rootsi normatiivile: neurootilisus, agressiivsus ja ekstra-
vertsus. 
Eestikeelse NEO-PI-R neurootilisuse dimensioon korreleerus kõige tuge-
vamalt SSP neurootilisuse faktoriga. NEO-PI-R ekstravertsus korreleerus positiiv-
selt SSP alaskaalade seikluste otsimise ja impulsiivsusega ning negatiivselt iso-
leerumise, psüühilise ärevuse, kehtestavuse puudumise, vastuvõtlikkusega 
stressile ning umbusklikkusega. NEO-PI-R faktor sotsiaalsus korreleerus posi-
tiivselt SSP alaskaala sotsiaalse soovitavusega, negatiivselt agressiivsuse-
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ärrituvuse, umbusklikkuse ja kibestumisega. NEO-PI-R faktorid meelekindlus 
ja avatus olid nõrgemalt seotud SSP-ga. NEO-PI-R meelekindlus korreleerus 
kõige enam SSP sotsiaalse soovitavuse ja avatuse faktor seikluste otsimisega. 
Kokkuvõtvalt, NEO-PI-R ja SSP uurimine kinnitas viimase skaala valiidsust. 
Erinevused kahe skaala vahel võivad olla tingitud sellest, et SSP on võrreldes 
NEO-PI-R-ga spetsiifilisema suunaga, püüdes kirjeldada isiksuse patoloogilisi 
nüansse. 
Kokkuvõtvalt näitas SSP eestikeelne versioon kõrget reliaablust ja valiidsust 
kõrvutatuna Rootsi originaalvalimiga ning ka viiefaktorilise isiksusemudeliga. 
Teises uuringus ei olnud olulisi erinevusi patsientide ja kontrollgrupi demo-
graafilistes näitajates. Komorbiidse PH patsientidel oli enam psüühilisi häireid 
perekonna anamneesis võrrelduna ainult PH patsientidega, samuti oli komor-
biidses PH grupis rohkem suitsetajaid. SSP alaskaalade analüüsis leiti PH 
patsientide ja tervete kontrollgrupi isiksuse omaduste vahel erinevused. Kõik 
SSP alaskaalad, välja arvatud isoleerumine ja füüsiline agressioon, olid PH 
patsientidel oluliselt nihkes võrreldes kontrollgrupiga, sealhulgas seikluste 
otsimine ja sotsiaalne soovitavus madalamad, kõik teised alaskaalad kõrgemad. 
SSP faktorid neurootilisus ja agressiivsus, kuid mitte ekstravertsus, olid oluliselt 
kõrgemad PH grupis võrreldes kontrollgrupiga. 
Komorbiidse paanikahäire ning kontrollgrupi võrdluses leiti oluline erinevus 
kõigis SSP alaskaalades, välja arvatud seikluste otsimine. Kõik alaskaalad olid 
komorbiidse PH grupis kõrgemate väärtustega, välja arvatud sotsiaalne soovi-
tavus, mis oli madalam. Ainult PH patsiendid demonstreerisid kõrgemat neu-
rootilisust ja agressiivsust, kuid ekstravertsus oli sarnane kontrollgrupiga. 
Kahe paanikahäirega patsientide grupi võrdluses olid nihked rohkem 
väljendunud komorbiidse PH grupis, erinevus leiti ärevuse alaskaalade, stressile 
vastuvõtlikkuse, kibestumise ja ärritatavuse skaaladel. Kolmest faktorist erines 
kahe PH grupi vahel ainult neurootilisus. 
Käesoleva paanikahäirega grupis võrreldes remissioonis patsientidega olid 
oluliselt kõrgemad väärtused ärevuse alaskaaladel ja stressile vastuvõtlikkusel, 
kuid mitte teistel skaaladel. SSP faktoritest oli ainult neurootilisus oluliselt 
kõrgem käesoleva PH patsientidel. 
Käesoleva PH-ga patsiendid näitasid võrreldes kontrollgrupiga olulist eri-
nevust mitmel SSP alaskaal, välja arvatud impulsiivsus, isoleeritus ja füüsiline 
agressioon. 
Seega võib uuringu tulemusel väita, et paanikahäirega patsiente iseloomus-
tavad väheadaptiivsed isiksusejooned, eriti kõrge neurootilisus ning tugev kal-
duvus somaatilisele ärevusele. 
Kolmandas uuringus leiti kõigi SSP alaskaalade T-skooride langemine 12 
nädalase farmakoloogilise ravi järel võrreldes algväärtusega, kuid ükski muutus 
ei olnud statistiliselt olulisel tasemel. Kõige rohkem vähenesid somaatiline 
ärevus, vastuvõtlikkus stressile ja psüühiline ärevus. 
Leiti mõned nõrgad, statistiliselt mitteolulised seosed SSP alaskaalade ja 
kliinilise seisundi hinnangu skaalade vahel. 
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Ükski SSP alaskaalade algväärtusest ei olnud oluliselt seotud ravivastusega. 
Ainult kõrgem SSP impulsiivsuse tase uuringu alguses oli lähedal statistiliselt 
olulisele ennustamaks remissiooni mittesaavutamist peale 12 nädalast ravi 
estsitalopraamiga. Algse impulsiivsuse tase oli statistilisele olulisele lähedaselt 




1. Demonstreerisime, et SSP eestikeelne versioon näitas aktsepteeritavaid 
psühhomeetrilisi omadusi. SSP mõõdab isiksuse jooni, mis on universaalsed 
ja haakuvad ühe varasema juhtiva isiksuseteooriaga. 
2. SSP suutis lisada asjakohast informatsiooni kliiniliselt olulistele isiksuse 
dimensioonidele paanikahäirega patsientidel. Me näitasime, et PH patsientide 
isiksuse struktuur on madala adaptiivsusega. Neid patsiente iseloomustab 
eelkõige kõrge neurootilisus ja somaatilise ärevuse väljendumine. 
3. Enam väljendub isiksusejoonte kõrvalekalle afektiivse komorbiidsusega 
paanikahäirega patsientidel. Agressiivsus oli seotud agorafoobia ja afektiivse 
komorbiidusega. 
4. Kuigi PH patsientide madala adaptiivsusega isiksus näitas kindlat suunda 
normaliseerumisele 12-nädalase antidepresssandi estsitalopraami raviga, ei 
leidnud me isiksusejoonte olulist seost kliinilise ravitulemusega. Parema 
farmakoloogilise ravivastusega kaasnes enam väljendunud paranemine 
isiksuse joontes, mida võib omistada üldiselt paremale enesetunnetusele 
paranemisel. 
5. Võimalikku ennustavat efekti PH ravis antidepressandiga näitas impulsiivus, 
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